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IDENTIFICATION OF PATHWAYS REQUIRED FOR THE
SURVIVAL OF INVERSION(16) ACUTE MYELOID LEUKEMIA
Yiqian Wang, Ph.D.
University of Nebraska, 2019
Supervisor: R. Katherine Hyde, Ph.D.
ABSTRACT
Inversion of chromosome 16 [inv(16)] acute myeloid leukemia (AML) generates
a fusion gene CBFB-MYH11. Approximately half of inv(16) AML patients eventually
relapse mainly due to the existence of leukemia stem cells (LSCs). Previous work using
a Cbfb-MYH11 knockin mouse model showed that the LSCs are enriched within
CSF2RB- population. Another gene upregulated by Cbfb-MYH11 encodes the cytokine
receptor IL1RL1. Using Cbfb-MYH11 knockin mice, we showed that LSCs exist in
multiple sub-populations defined by their immunophenotype, and IL1RL1 is expressed
by cell populations with high LSC activity. We also found that treatment of IL-33, the
ligand for IL1RL1, promoted cell survival in vitro. Our results imply that therapeutic
approaches based on a single cell surface molecule antigen may not work against the
entire, diverse population of LSCs.
The CBFB-MYH11 fusion gene is expressed in all LSCs but not in normal cells.
Thus, targeting CBFB-MYH11 may have potential as a therapeutic strategy. Here, we
used a new knockin mouse model allowing for deletion of Cbfb-MYH11 after leukemic
transformation and demonstrated that the loss of the Cbfb-MYH11 caused apoptosis and
decreased colony-forming ability in vitro. By transducing leukemia cells from CbfbMYH11 knockin mice with doxycycline inducible short hairpin RNA (shRNA) targeting
MYH11 and transplanting into recipient mice. We found that Cbfb-MYH11 knockdown
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significantly reduced the leukemic burden in vivo. Thus, our data indicates that CbfbMYH11 is required for the survival of inv(16) leukemia cells.
Given the role of Cbfb-MYH11 in leukemia cell survival, it is important to develop
targeted therapies to inhibit the fusion gene activity. In collaboration with Dr. David
Oupicky’s laboratory, we tested a polymeric CXCR4 antagonist (PCX) which can deliver
short interfering RNA (siRNA). We found that PCX exerts a cytotoxic effect in leukemia
cells and successfully delivered siRNAs into leukemia cells, as well as caused
apoptosis. Our results imply that using PCX to deliver siRNAs targeting key genes is a
potential strategy for the treatment of AML. Overall, our results provide insights into
promising molecular therapeutic agents for treating AML patients in the future.
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CHAPTER I
Introduction
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1. Acute Myeloid Leukemia
1.1 Overview and definition of AML
Leukemia is one of the leading causes of cancer death in the United States, with
approximately 60,000 new cases and 24,000 deaths every year (Siegel, Miller et al.
2018). Acute myeloid leukemia (AML) accounts for 19,000 of these new cases and
11,000 deaths, and represents one of the most common subtypes of leukemia. AML is
an aggressive malignant disease predominantly of adults (Harris, Jaffe et al. 1999, Estey
and Dohner 2006). AML is characterized by uncontrolled proliferation of clonal immature
myeloid progenitor cells unable to differentiate into mature blood cells, which further
disrupts normal hematopoiesis (Dohner, Weisdorf et al. 2015, Thomas and Majeti 2017).
AML patients often show symptoms at the time of presentation resulting from bone
marrow (BM) failure and organ infiltration including anemia, neutropenia, hepatomegaly,
joint pain and swollen, bleeding gums (Suriya and Aleem 2010, Dohner, Weisdorf et al.
2015). AML is now cured in 35-40% of adult patients who are younger than 60 years of
age, but those patients older than 60 years of age have a worse prognosis (Dohner,
Weisdorf et al. 2015, Saultz and Garzon 2016). Therefore, it is important to improve our
understanding of the biology and molecular events of AML in order to develop more
effective treatment agents.

1.2 Classification of AML
Identifying the subtypes of AML is important to determine the best treatment for
patients because different subtypes of AML often require different treatment strategies.
However, the classification of AML is fairly complicated due to the diversity of
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morphology, clinical features and genetics. Two main classification systems have been
developed to divide AML into different subtypes.
In 1976, the morphological classification of AML was first recognized by the
French-American-British (FAB) cooperation group and has been revised in the ensuing
years (Bennett, Catovsky et al. 1976, Bloomfield and Brunning 1985). This FAB system
divides AML into 9 subtypes, labeled M0 through M7 based on the maturation status of
the leukemic blast cells and cytochemical staining.
However, in recent years, it has been recognized that FAB classification failed to
identify some recurrent genetic abnormalities including chromosome inversions,
translocations and additional mutations in AML. To better classify AML, a new
classification system was proposed by the World Health Organization (WHO) based on
the underlying genetic abnormalities and/or pathophysiologic characteristics (Schiffer
and Gurbuxani 2017). In contrast to the FAB system, which mainly relies on morphologic
features and cytochemical studies, WHO classification integrates morphology as well as
cytogenetic information into the classification scheme of AML (Campo, Swerdlow et al.
2011). Based on pretreatment cytogenetic findings, AML patients are stratified into three
risk groups, favorable, intermediate or adverse to direct risk-adapted therapy (Wang and
Bailey 2015). According to cytogenetic abnormalities, patients have been classified into
good [such as t(8;21), or t(15;17)], poor [such as those with inv(3)/t(3;3), MLLrearranged AML, or complex cytogenetics, balanced] or intermediate cytogenetic risk
groups [such as cytogenetic normal (CN)-AML] (Balgobind, Raimondi et al. 2009, Wang
and Bailey 2015). Molecular genetics also need to be taken into consideration for
appropriate selection and stratification of therapy in AML patients. For example,
favorable mutations include Nucleophosmin 1 (NPM1) and CCAAT/enhancer binding
protein α (CEBPA) gene mutations (Preudhomme, Sagot et al. 2002, Falini, Mecucci et
al. 2005). The internal tandem duplication in Fms-like tyrosine kinase 3 (FLT3-ITD)
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mutation and overexpression of ecotropic viral integration-1 (EVI1) mutation are
associated with an inferior prognosis (DeZern, Sung et al. 2011, Yuan, Wang et al.
2015).

1.3 Driver mutations in AML
AML requires multiple driver mutations to contribute to leukemogenesis. The “two-hit”
theory divides mutations into two classes. Class I mutations, which include KIT, RAS
and FLT3, improve the leukemia blast cells’ ability to proliferate or survive. Those
mutations commonly regulate receptor tyrosine kinase (RTK) signaling pathways, which
further initiates intracellular signaling events including proliferation, survival, and
migration (Hubbard and Till 2000). Class II mutations typically prevent the myeloid
differentiation of the leukemia blast cells. This hypothesis has been updated recently to
include new types of mutations. For example, mutations of epigenetic modifiers,
Isocitrate dehydrogenase 1 and 2 (IDH1/2) and DNA (cytosine-5)-methyltransferase 3A
(DNMT3A), have been found to occur frequently in AML. The deregulated epigenetic
modifiers can cooperate with both Class I and Class II mutations and represent attractive
new therapeutic opportunities for AML (Shih, Abdel-Wahab et al. 2012, Naoe and Kiyoi
2013).

1.4 Prognostic factors and survival
Two main subgroups of prognostic factors have been identified that can influence
the outcome of AML patients: patient-related and AML-related factors. The former
includes age, organ dysfunction, performance status, and comorbid conditions
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(Appelbaum, Gundacker et al. 2006, Kantarjian, O'Brien et al. 2006). Age is a
considerable obstacle for achieving better outcomes in AML patients older than 60 years
old. Importantly, the combined effect from age and performance status needs to be
taken into consideration in terms of predicting 28-day mortality (Appelbaum, Gundacker
et al. 2006). AML-related factors include cytogenetic and molecular genetic prognostic
abnormalities, which have been discussed above.

1.5 Leukemia stem cells in AML
Leukemia stem cells (LSCs) in AML were the first described cancer stem cells
(CSCs). LSCs were thought to comprise a small minority of cells within the leukemic
blast population and reside at the apex of a cellular hierarchy able to generate the whole
population of AML blast cells (Lapidot, Sirard et al. 1994, Bonnet and Dick 1997). LSCs
are thought to be derived from HSCs or more committed progenitors, being able to
initiate and perpetuate the disease after transplantation into irradiated recipients due to
their self-renewal potential (Wang, Huang et al. 2017). From a clinical perspective, it has
been recognized that LSCs are resistant to chemotherapy and the likely cause of
relapse (Dick 2008, Saultz and Garzon 2016). Therefore, eradication of LSCs is a
principal aim of many novel therapeutics currently under development.
Although genetically abnormal, LSCs have been thought to share some
properties with normal hematopoietic stem cells (HSCs), including self-renewal,
quiescence, and the expression of similar cell surface markers (Lapidot, Sirard et al.
1994, Bhatia, Wang et al. 1997, Bonnet and Dick 1997). Pioneer studies by John Dick
demonstrated that, like HSCs, LSCs were enriched in the CD34+ CD38- fraction in AML.
The CD34+ CD38- LSCs are not only able to initiate leukemia in sub-lethally irradiated
immunodeficient mice, but also to maintain leukemia in serial transplantation. However,
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one study using a mouse model of AML initiated by the fusion gene MLL-AF9 (mixed
lineage leukemia-AF9) provided findings contradictory to earlier work. Somervaille and
Cleary found that LSCs are not rare nor are they quiescent (Somervaille and Cleary
2006). Moreover, they found that LSCs reside in the more differentiated myeloid lineage
compartment (Somervaille and Cleary 2006). Consistent with this finding, the same
group later found that human LSCs marked by the cell surface molecule CD93 are
predominantly cycling, and non-quiescent in mixed lineage leukemia (MLL)-rearranged
AML (Iwasaki, Liedtke et al. 2015).
Many studies have tried to identify markers unique for LSCs to prospectively
separate LSCs from HSCs. The ultimate goal is to achieve clinical applications. Some
identified cell surface markers that are upregulated in LSCs include CD123, CD44,
CD96, TIM3, and CD93 (Jordan, Upchurch et al. 2000, Jin, Hope et al. 2006, Hosen,
Park et al. 2007, Jan, Chao et al. 2011, Li and Bhatia 2011, Iwasaki, Liedtke et al. 2015).
However, the identified markers for LSCs may be expressed only in specific genetic
subtypes of AML, and thus targeting those markers cannot be applied to eradicate LSCs
in all types of AML. However, these LSC markers may still be helpful for monitoring
leukemia progression in patients.
To date, no unique marker has been found to be universally expressed on LSCs
but not on normal HSCs. The challenge may be caused by the intrinsic heterogeneity of
AML both among different patients (interpatient heterogeneity) and within a single
patient (intrapatient heterogeneity) (Thomas and Majeti 2017).

1.6 Treatment of AML
1.6.1

Induction and consolidation therapy
Treatment of AML is divided into induction therapy and consolidation therapy.
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The standard regimen for AML induction therapy is the so-called “7+3” regimen: 3 days
of an anthracycline and 7 days of cytarabine (Ara-C) (Estey and Dohner 2006, Rowe
2009). The main function of anthracyclines in treating AML is to induce DNA damage
and apoptosis. The commonly used anthracyclines include daunorubicin, doxorubicin,
idarubicin or synthetic anthracycline analogues like mitoxantrone, which induces DNA
damage (Burnett 2012, Roboz 2012). Ara-C interferes with DNA synthesis during S
phase of cell cycle and blocks mitosis (Evans, Musser et al. 1961, Talley and
Vaitkevicius 1963). The main goal of induction therapy is to achieve complete remission
(CR) (Cheson, Bennett et al. 2003). Consolidation therapy, also known as postremission therapy, is given to patients to prevent relapse and decrease minimal residual
disease (MRD) after patients achieve the first remission (CR1) (Dohner, Weisdorf et al.
2015, Saultz and Garzon 2016). Several types of post-remission strategies have been
evaluated: consolidation chemotherapy, autologous hematopoietic stem cell
transplantation (auto-HSCT), and allogeneic HSCT (allo-HSCT) (Rowe 2009).

1.6.2

Molecularly targeted therapy
Currently, most patients with AML are treated with similar chemotherapeutic

drugs. However, the 5-year survival in AML patients younger than age 60 is only 40%,
and the prognosis for AML patients after achieving CR, especially those older than age
60 still remains dismal, with only 5%-8% of the patients being alive 5 years after the
diagnosis (Alibhai, Leach et al. 2009, Burnett, Wetzler et al. 2011). Thus, based on the
limitations of current treatment options, more effective therapeutic agents are required.
With the progress in understanding the pathogenesis of AML, as well as the discovery of
new molecular markers in recent years, molecularly targeted approaches have been
widely investigated and show promising results in clinical trials. Current targeted
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therapies approved by the FDA include all-trans retinoic acid and arsenic trioxide for
treating acute promyelocytic leukemia (APL), a subtype of AML, characterized by the
t(15;17) translocation, occurring in 10-15% of AML cases (Antman 2001, Yamamoto
and Goodman 2008). Several inhibitors targeting FLT-3 have been developed and can
be used as a single agent in relapsed AML. FLT3 mutations account for approximately
30-35% of AML cases and are often associated with either high relapse rate and poor
outcomes, especially the FLT3 internal duplication (FLT3-ITD) mutation (Bose, Vachhani
et al. 2017). In addition, the strategy of combining FLT3 inhibitors with induction or
consolidation therapy has shown satisfactory responses from some pilot studies
(Ravandi, Cortes et al. 2010, Roboz 2012).
Mutations in some epigenetic modifiers, for example, IDH1 and IDH2, occur in
approximately 8-12% of AML patients. The result of each mutation leads to an arrest of
hematopoietic differentiation due to a hypermethylated genome. An inhibitor targeting
IDH2 has been approved by the FDA for the treatment of relapsed/refractory AML
(Kayser and Levis 2018). Other inhibitors of IDH1/2 mutations in clinical development
have been reported to be effective when used as single agent or in combination with
conventional chemotherapy (DiNardo, Ravandi et al. 2015, Chaturvedi, Herbst et al.
2017).
Overall, these findings suggest that molecularly targeted therapy has clinical
value for AML patients. However, AML is rarely driven by a single genetic event. Thus,
to ultimately cure patients, it is necessary to further understand the molecular biology of
AML and find the appropriate combinations of therapeutic agents.

1.6.3

Leukemia stem cell-targeted therapy
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In addition to molecularly targeted approaches, targeting therapy-resistant LSCs
also represents a major area of drug development in AML (Pollyea and Jordan 2017).
One approach of targeting LSCs is based on understanding the immunophenotypes of
LSCs by performing functional studies using immunodeficient mice as primary AML
xenografts. Earlier studies indicated that LSCs share some cell surface antigens with
normal hematopoietic stem and progenitor cells (HSPCs), including CD34 and CD38
(Guzman, Neering et al. 2001). In addition, some antigens have been found that are
aberrantly upregulated in the LSC population, which can be used to distinguish LSCs
from normal hematopoietic stem cells (HSCs). However, more recent work indicates
that, in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the expression of LSC
markers CD34 and CD38 is not stable over time, suggesting that LSCs are likely not to
be organized in a strict hierarchical differentiation scheme characterized by these two
markers. These data indicate that LSC’s immunophenotype is plastic, which would make
this approach less effective than it had been previously assumed. Overall, development
of effective therapeutic strategies to target LSCs largely depends on fully understanding
the pathways important for LSC activity.

2 Inversion 16 AML
Inversion of Chromosome 16 [inv(16)(p13q22)] occurs in 10-15% of all AML
cases, representing one of the most frequent chromosomal translocation in AML. Nearly
all patients with AML subtype M4 with eosinophilia (FAB classification) have inv(16) (Liu,
Tarle et al. 1993, Dunphy 1999). The standard treatment for AML patients with inv(16)
includes cytarabine and anthracyclines. Current treatments result in a good initial
response in inv(16) AML patients. However, the long-term overall survival remains low,
and around 50% of patients eventually relapse (Ravandi, Burnett et al. 2007, Pulsoni,

10

Iacobelli et al. 2008, Bhatt, Kantarjian et al. 2013). Therefore, a better understanding of
the biology of inv(16) AML is important for future drug development in order to prevent
disease relapse.

2.1 Core binding factor
Half of all AML cases arise from recurrent chromosomal rearrangements, which
affect transcription factors that have important functional roles in normal hematopoietic
processes (Look 1997). Two different chromosomal rearrangements [inv(16) and the t
(8;21) translocation] target members of the core binding factor (CBF) family of
transcription factors. In total, the CBF-AMLs account for approximately 20% of AML
cases (Liu, Tarle et al. 1993, Look 1997, Castilla, Perrat et al. 2004, Zeisig,
Kulasekararaj et al. 2012). The 5-year survival for patients with CBF-AML is only 50%
(Chen, Gau et al. 2007, Jung, Maeng et al. 2014). CBF is a heterodimeric transcription
factor complex consisting of α and β subunits. The α-subunit of CBF is encoded by the
Runt-related transcription factor (RUNX) genes, whereas the β-subunit is encoded by
the CBFB gene (Castilla, Perrat et al. 2004, Jung, Maeng et al. 2014). RUNX (encoded
by RUNX1, RUNX2, and RUNX3 genes) directly binds to the DNA promoter sequences
of target genes critical for hematopoiesis, whereas the β-subunit of CBF (CBFβ)
enhances the DNA affinity of α-subunits and prevents their proteasomal degradation
(Castilla, Garrett et al. 1999, Tang, Crute et al. 2000, Castilla, Perrat et al. 2004, Jung,
Maeng et al. 2014). RUNX binds to DNA via its Runt homology domain (RHD) (Meyers,
Downing et al. 1993, Ogawa, Inuzuka et al. 1993, Wang, Wang et al. 1993, Okuda, van
Deursen et al. 1996). Among all CBF-AMLs, approximately one half are caused by
inv(16) AML. The translocation t(16;16)(p13;q22) generates the same fusion gene as
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inv(16) but with much lower incidence (Castilla, Garrett et al. 1999, Tang, Crute et al.
2000).

2.2 CBFβ-SMMHC oncofusion protein
The inversion of chromosome 16 disrupts the CBFB gene on the q arm and the
MYH11 gene on the p arm (Liu, Hajra et al. 1995, Castilla, Wijmenga et al. 1996). The
MYH11 gene encodes the smooth muscle myosin heavy chain (SMMHC). The fusion
gene CBFB-MYH11 encodes the chimeric fusion protein CBFβ-SMMHC (Figure 1.1).
The expression of the fusion protein is thought to be the initiating event in inv(16) AML.
However, to obtain full-blown leukemia, cooperating mutations are also required (Liu,
Tarle et al. 1993, Liu, Seidel et al. 1994).
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Figure 1.1. Schematic representation of an inversion on chromosome 16.
The inversion of chromosome 16 involves the CBFB gene at 16q22 and MYH11 gene at
16p13.
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2.2.1

Structure and function of CBFβ-SMMHC

The fusion protein has the N-terminal amino acids (aa) (1-165) of CBFβ and the Cterminal amino acid of SMMHC (Liu, Hajra et al. 1995, Shigesada, van de Sluis et al.
2004). The first 165 aa is fused to the coiled-coil rod domain of SMMHC, which is
responsible for dimerization and multimerization of the myosin molecule into filaments
(Le Beau, Larson et al. 1983, Liu, Tarle et al. 1993, Shigesada, van de Sluis et al. 2004).
The multimerization process depends on a domain known as assembly competence
domain (ACD), which is located within exon 40 of SMMHC (Sohn, Vikstrom et al. 1997,
Ikebe, Komatsu et al. 2001, Kummalue, Lou et al. 2002). A repression domain at the Cterminus on SMMHC is able to interact with transcriptional co-repressors such Sin3a and
HDAC8 (Pulikkan and Castilla 2018). The resulting fusion protein can dimerize with
RUNX1, leading to the formation of CBFβ-SMMHC/RUNX1 complex (Liu, Tarle et al.
1993). While CBFβ binds to RUNX1 via the RUNX binding domain (RBD), a novel
binding site at the N-terminus of CBFβ-SMMHC, high-affinity binding domain (HABD),
binds to RUNX1 at 10-fold higher affinity than to CBFβ alone (Figure 1.2) (Goger, Gupta
et al. 1999, Lukasik, Zhang et al. 2002, Pulikkan and Castilla 2018). As a result, CBFβSMMHC binds RUNX1 at two sites, which is associated with higher binding affinity
(Lukasik, Zhang et al. 2002). Initially, it was proposed that CBFβ-SMMHC inhibits
RUNX1-mediated transcription during leukemogenesis, resulting in transcriptional
repression of RUNX1 target genes (Shigesada, van de Sluis et al. 2004). More recently,
CBFβ-SMMHC was found to lead to a block in differentiation by a RUNX1-repression
independent mechanism. Instead, CBFβ-SMMHC acts mainly by altering RUNX1
activity. Thus, CBFβ-SMMHC can act as a transcriptional repressor as well as promote
transcription activation (Hyde, Kamikubo et al. 2010, Mandoli, Singh et al. 2014).
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Figure 1.2. Schematic representation of protein organization of CBFβ-SMMHC.
Diagram representing the indicated domains of the fusion protein. RBD: RUNX1-binding
domain. HABD: high-affinity binding domain. ACD: assembly competence domain.
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2.2.2 Cooperating mutations with CBFβ-SMMHC
The expression of fusion protein CBFβ-SMMHC is the driver oncogenic event in
inv(16) AML, but is not sufficient to induce the leukemic phenotype. Cooperating
mutations are required for leukemogenesis (Castilla, Garrett et al. 1999). The expression
of the fusion gene CBFB-MYH11 is shown to behave as a class II mutation and requires
Class I cooperating mutations for leukemic transformation. The cooperating mutations
found most frequently in CBFB-MYH11-expressing leukemia cells including KIT, NRAS,
KRAS, and FLT3 (Bowen, Frew et al. 2005, Bacher, Haferlach et al. 2006, Muller, Duque
et al. 2008).
KIT, a receptor for stem cell factor (SCF), belongs to the class III RTK family and
is highly expressed in early progenitor cells. Upon binding to SCF, KIT goes through
dimerization and autophosphorylation on the tyrosines in the juxtamembrane domain
(Mol, Lim et al. 2003). Activation of KIT further activates intracellular serine/threonine
protein kinase signaling cascades, which are critical for the normal growth and
development of the cell. KIT is more frequently mutated in inv(16) AML as compared to
other subtypes of AML (Muller, Duque et al. 2008). Mutations on KIT in inv(16) AML
includes D816V and D816Y, leading to constitutive activation of KIT signaling and are
thought to be associated with inferior prognosis for inv(16) AML patients (Paschka,
Marcucci et al. 2006, Muller, Duque et al. 2008). A recent study showed that
coexpression of Cbfb-MYH11 and KIT D816 mutations leads to accelerated
development of leukemia compared with cells only carrying Cbfb-MYH11. This study
indicates that KIT with D816 mutations cooperate with CBFB-MYH11 for
leukemogenesis (Zhao, Melenhorst et al. 2012).
FLT3 gene mutations are found in less than 10% of inv(16) AMLs (Muller, Duque
et al. 2008). Previous study has found that mice with FLT3-ITD knock-in allele develop
myeloproliferative disease (MPD), and that mutation may also confer enhanced
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proliferation and survival capabilities, especially in progenitor cells (Lee, Tothova et al.
2007).
NRAS/KRAS are mainly involved in the Ras/Raf/mitogen-activated protein kinase
(MEK)/extracellular signal-regulated kinase (ERK) signaling pathway important for
cellular proliferation (Karnoub and Weinberg 2008). Somatic mutations in NRAS or
KRAS lead to constitutively active RAS proteins and downstream molecules (Beaupre
and Kurzrock 1999). Xue et al demonstrated that allelic coexpression of Cbfb-MYH11
and the Nras G12D mutation (NrasG12D) promoted the proliferation and survival of
preleukemic myeloid progenitors in the bone marrow, leading to a more aggressive AML
compared with controls expressing only Cbfb-MYH11 or NrasG12D (Xue, Pulikkan et al.
2014).
Overall, these observatios indicate that Cbfb-MYH11 cooperates with “secondary
mutations” that are key components of cytokine signaling during leukemogenesis, thus
providing a survival advantage for the preleukemic HSPC population. Due to intrapatient
heterogeneity, a single AML patient can have subclones with different cooperating
mutations even though they share the same founding mutation. More importantly,
different mutation combinations have varying levels of sensitivity to therapy. As a result,
the same inv(16) patient may show a different spectrum of cooperating mutations than at
diagnosis (Pulikkan and Castilla 2018). Therefore, drugs targeting Cbfb-MYH11 activity
are more likely to be more effective than targeting the cooperating mutations.

2.3 Conditional Cbfb-MYH11 knock-in mouse model
Previously, the Cbfb-MYH11 gene was knocked into the endogenous Cbfb locus
to generate Cbfb-MYH11 knock-in mice (Cbfb+/MYH11). Heterozygous mice for this allele
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(Cbfb+/MYH11) were observed to have a complete block in definitive hematopoiesis and
exhibited embryonic lethality (Castilla, Wijmenga et al. 1996). An inv(16) conditional
knock-in mouse model was developed called Cbfb+/56M (Kuo, Landrette et al. 2006). In
that model, a cassette with Cbfb exons 5 and 6 and a stop codon are flanked by loxP1
sites with MYH11 downstream of the second loxP1 site (Figure 1.3). In this model,
expression of Cbfb-MYH11 is induced upon Cre-mediated loxP deletion. Most
commonly, Cre is expressed from the inducible Mx1 promoter, which can be activated by
polyinosine-polycytidylic acid (pIpC) injection. To accelerate leukemia development,
mice are also treated with multiple rounds of pIpC (Kuo, Landrette et al. 2006, Hyde,
Kamikubo et al. 2010).

2.4 Leukemia stem cells in inv(16) AML
It has been proposed that leukemia stem cells (LSCs) share important biological
properties with normal HSCs, including cell-cycle quiescence, cell surface marker
expression and resistance to chemotherapy. However, recent studies demonstrate that
LSCs can be actively cycling or more mature than previously predicted (Somervaille and
Cleary 2006, Iwasaki, Liedtke et al. 2015, Thomas and Majeti 2017). Previously, by
examining data from Cbfb+/MYH11 embryos and leukemic mice expressing Cbfb-MYH11
by microarray technology. Hyde et al found that the fusion gene uniquely deregulated
genes associated with aberrant myeloid differentiation (Hyde, Kamikubo et al. 2010). In
addition, by using the conditional Cbfb-MYH11 knock-in mouse model, they showed that
expression of Cbfb-MYH11 induces a population of abnormal, immature myeloid cells
that express the cytokine receptor colony-stimulating factor 2 receptor, beta (CSF2RB)
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Figure 1.3. Schematic representation of the conditional Cbfb-MYH11 knock-in
mouse model.
The Cbfb allele exons 5 and 6 are flanked by loxP1 site with MYH11 downstream by the
second loxP1 site. The expression of Cbfb-MYH11 is induced by Cre-mediated loxP
deletion.
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(Hyde, Kamikubo et al. 2010). Csf2rb gene was found to be the second-most upregulated gene in the Cbfb-MYH11+ embryos and expressed in virtually all human
inv(16) leukemia samples (Hyde, Kamikubo et al. 2010). In the previous report, 14 days
after Cbfb-MYH11 was induced in nonleukemic mice, lineage-negative (lin-) bone
marrow cells were sorted into CSF2RB- and CSF2RB+ cell populations and plated for
colony assay. They found that CSF2RB+ cells produced significantly fewer colonies than
CSF2RB- cells. In addition, CSF2RB- cells were able to give rise to CSF2RB+ cells based
on staining of the colonies derived from CSF2RB- population.
By sorting and transplanting equal numbers of CSF2RB- and CSF2RB+ cells into
recipient mice using the conditional Cbfb-MYH11 knock-in mouse model, they found that
the presumably more immature population, CSF2RB- cells, caused leukemia faster after
secondary transplantation compared to CSF2RB+ cells, indicating that CSF2RB- cells are
enriched for LSC activity in vivo. This finding further implies that CSF2RB is a potential
cell surface marker to isolate LSCs in Cbfb-MYH11-induced leukemia. Overall, this study
indicates that Cbfb-MYH11 causes a differentiation blockage along with continued
upregulation of genes (Hyde, Kamikubo et al. 2010). Importantly, CSF2RB can be used
as a negative selection marker to enrich LSCs from Cbfb-MYH11 mice. However, this
study did not address whether it is possible to use additional markers to further enrich for
LSCs within the CSF2RB- population.

3

Interleukin 1 receptor-like 1
It is well acknowledged that cytokines are secreted by various types of cells and

play an important role in normal hematopoiesis (Coondoo 2011). In AML, cytokines can
be produced by leukemic blasts and BM stromal cells. However, the precise contribution
by cytokines to leukemogenesis or leukemia maintenance is not known (Kupsa, Horacek
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et al. 2012). Aberrant cytokine signaling has been found to be associated with
proliferation, drug resistance and prognosis in leukemia (Sanchez-Correa, Bergua et al.
2013).
In previous work, Hyde et al identified a cytokine receptor, IL1RL1 (ST2), which
is highly expressed within both the CSF2RB- and CSF2RB+ populations from mice
expressing Cbfb-MYH11 (Hyde, Kamikubo et al. 2010). IL1RL1 is an interleukin 1 (IL-1)
type receptor that is expressed on a subset of T cells and different types of mature
myeloid cells (Griesenauer and Paczesny 2017, Cayrol and Girard 2018, Dinarello
2018). This receptor is encoded by the IL1RL1 gene and belongs to the Toll-like/IL-1
receptor (TLR/IL-1R) superfamily (Tominaga, Jenkins et al. 1991). IL1RL1 has two main
splice forms: the transmembrane isoform and the soluble isoform lacking the
transmembrane domain (Liew, Pitman et al. 2010).

3.1 The IL-33/IL1RL1 axis
The cytokine interleukin 33 (IL-33) was first identified in 2005 by Schmitz et al
(Schmitz, Owyang et al. 2005). IL-33 belongs to interleukin-1 (IL-1) family of cytokines
and is the only known ligand of IL1RL1. Binding of IL-33 to IL1RL1 on normal myeloid
cells triggers a pro-inflammatory response involving the release of additional cytokines,
increased proliferation, and/or a block in apoptosis. IL-33 was found to have similar
biological functions as other IL-1 family members, IL-1 and interleukin-18 (IL-18), both of
which are involved in the host response to the inflammatory, infectious, or immunological
challenge (Dinarello 1994, Dinarello 2000, Schmitz, Owyang et al. 2005). IL-33 is
produced in a precursor form (pro-IL-33), consisting of a non-classical nuclear
localization sequence (NLS) at the N-terminus and a domain with cytokine activity at the
C-terminus (Roussel, Erard et al. 2008). Pro-IL-33 goes through proteolytic processing
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by several proteases including calpain, elastase and cathepsin G in the nucleus. The
final mature product of IL-33 is an 18 kDa form, which only contains the cytokine domain
(Martin 2013). As a cytokine, IL-33 has been found to form a complex with its receptor,
IL1RL1 (ST2), as well as its co-receptor, IL-1 receptor accessory protein (IL1RAcP). In
addition, the soluble form of IL1RL1 binds IL-33 directly, acting as a decoy receptor
(Liew, Pitman et al. 2010). As a result, soluble IL1RL1 binding to IL-33 can inhibit its
binding to membrane-bound IL1RL1 and downstream signaling (Schmitz, Owyang et al.
2005, Hayakawa, Hayakawa et al. 2007).

3.2 IL-33/IL1RL1 signaling
Upon binding to its receptor, myeloid differentiation primary-response protein 88
(MYD88), and IL-1R-associated kinase 1 and 4 (IRAK1 and IRAK4, respectively) are
recruited to the receptor complex and activate signaling pathways. Two well-defined
signaling pathways downstream of IL1RL1 include the transcription factor nuclear factorκB (NF-κB) and the mitogen-activated protein kinase (MAPK) pathway, which is
regulated by the MAPKs extracellular signal-regulated kinase (ERK), p38 and JUN Nterminal kinase (JNK). In addition, the two pathways may act together to induce the
expression of additional cytokines and chemokines (Figure 1.4). In addition, there exist
cell-specific variations in the signaling pathways mediated by IL-33/IL1RL1 axis. In mast

22

IL-33

IL1RAP

IL1RL1

MYD88

IRAK1

NF-κB

MAPKs

ERK

JNK

IRAK4

Plasma
membrane

P38

IL-1β, IL-3, IL-6
production

Figure 1.4. IL-33/IL1RL1 signaling pathway.
IL-33 signals through IL1RL1 and IL-1 receptor accessory protein (IL-1RAP) dimers,
which further leads to the recruitment of MYD88 complex and downstream pathways.
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cells, IL-33 activates NF-κB by Ca2+ influx following the activation of phospholipase D
(PLD) and sphingosine kinase (SPHK). Remarkably, that pathway is important for the
degranulation of IgE-primed mast cells and the production of cytokines including IL-1β,
IL-3, and IL-6 (Liew, Pitman et al. 2010). In fibroblasts, IL-33 binding leads to TRAF6,
which is the factor required for IRAK recruitment leading to JNK, p38 and NF-κB
activation, but not ERK activation (Funakoshi-Tago, Tago et al. 2008).

3.3 IL-33/IL1RL1 pathway in blood malignancies
IL-33 is well recognized to be able to regulate the activities of normal myeloid
cells including their migration and their roles in the immune response (Kim, Kim et al.
2014, Furukawa, Moriyama et al. 2017). From more recent studies, a role for IL-33 in
blood malignancies has been reported, as well. The study by Levescot et al suggests
that IL1RL1 is upregulated in chronic myeloid leukemia (CML) cells by the fusion protein
BCR-ABL and that treatment with IL-33 promotes resistance to the BCR-ABL inhibitor
imatinib (Levescot, Flamant et al. 2014). In addition, IL1RL1/IL-33 signaling leads to
dysregulated myelopoiesis in mouse models of myeloproliferative neoplasms (MPN)
(Mager, Riether et al. 2015). However, the role of the IL1RL1/IL-33 axis in AML has not
been established. A recent study by Qin et al in 2016 showed that exogenous
recombinant IL-33 was capable of inhibiting leukemia growth and prolonging the survival
of leukemia-bearing mice by promoting an anti-leukemia CD8+ T-cell response (Qin,
Dominguez et al. 2016). A more recent study described a critical role for IL-33 in acute
basophilic leukemia (ABL) caused by the MYB-GATA1 fusion gene (Ducassou, ProuzetMauleon et al. 2017). In that study, IL-33 was found to be involved in the enhancement
of the basophilic differentiation of both normal cells and leukemia cells. The data suggest
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that the IL-33/IL1RL1 axis can promote the survival and proliferation of myeloid cells in
hematological malignancies. However, under certain circumstances, IL33/IL1RL1 can
induce an anti-leukemia effect. These contradicting findings may be due to the use of
different mouse models or analysis of different downstream target genes induced by the
IL33/IL1RL1 axis. Thus, further investigation on the contribution of IL33/IL1RL1 in AML
maintenance is required.

4 C-X-C Chemokine Receptor Type 4
Leukemia cells also express a wide variety of chemokine receptors that are
important to their homing and egress from the bone marrow niche by interacting with
specific chemokines (Cho, Kim et al. 2017, Mukaida, Tanabe et al. 2017, Sison, Kurre et
al. 2017). Chemokines are a family of chemoattractant cytokines produced by the
marrow stroma and epithelial cells. They interact with their respective 7-transmembrane
spanning receptors, which are coupled with heterotrimeric GTP-binding proteins. The
interaction between chemokines and their cognate receptors is capable of inducing
concentration gradient-driven chemotactic migration of cells. Chemokine receptors are
divided into four groups depending on the number and spacing of N-terminal cysteines
(CX, CC, CXC, and CX3C) (Le, Zhou et al. 2004, Wang, Xie et al. 2016, Mukaida,
Tanabe et al. 2017). CXC receptor 4 (CXCR4) is widely expressed in various human
cancer cells and promotes the metastasis to distant sites. In addition, CXCR4
expression is often associated with poor survival, which makes it important to develop
drugs to inhibit CXCR4 activity (Akashi, Koizumi et al. 2008, Li, Zhu et al. 2012).
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4.1 CXCR4/CXCL12 signaling
CXCR4 is known to be overexpressed in approximately 23 human cancers. It
binds to its cognate chemokine C-X-C motif chemokine (CXCL12, also called SDF-1),
which is expressed in multiple normal tissues as well as immune cells, stromal
fibroblasts and cancer cells (Guo, Wang et al. 2016, Janssens, Struyf et al. 2018).
CXCL12 binds to CXCR4 and induces the internalization of CXCR4 as well as
downstream intracellular signaling. These processes promote translocation of CXCR4 to
the cytoplasm and to the nucleus from the cell membrane (Chatterjee, Behnam Azad et
al. 2014). A heterotrimeric G protein composed of α and βγ subunits is coupled with
CXCR4. After binding to CXCL12, CXCR4 undergoes a conformational change and
activates the exchange of GDP with GTP on the α subunit, which leads to the
dissociation of the α and βγ subunits (Pozzobon, Goldoni et al. 2016). The βγ subunit is
able to activate signaling enzymes including phospholipase C-β (PLC-β) and
phosphatidylinositol 3-OH kinase (PI3K). Further, PLC-β cleaves phosphatidylinositol
(4,5)-bisphosphate into inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG). IP3
induces the release of Ca2+ from intracellular stores and DAG activates protein kinase C
by working in conjunction with Ca2+, which further stimulates mitogen-activated protein
kinase (MAPK) and promotes cell migration (Mellado, Rodriguez-Frade et al. 2001,
Goldsmith and Dhanasekaran 2007, Chatterjee, Behnam Azad et al. 2014, Pozzobon,
Goldoni et al. 2016). By activating PI3K, Gα and βγ subunits further lead to the
phosphorylation of focal adhesion kinase, Crk-associated substrate (p130Cas), and the
cytoskeletal protein paxillin, thus contributing to the reorganization of the actin
cytoskeleton and changes critical for cell migration (Wang, Park et al. 2000, Zhang,
Wang et al. 2001). In addition, Gα is involved in different signaling pathways through
PI3K-AKT-NF-κB, MEK1/2, and ERK1/2 axes and regulates cell survival (Teicher and
Fricker 2010). Importantly, the homodimerization of CXCR4 leads to G protein-
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independent signaling via JAK-STAT pathway, which is correlated with changes in cell
morphology and further chemotactic responses (Figure 1.5) (Mellado, Rodriguez-Frade
et al. 2001). In addition, two G protein-independent pathways have been reported in
CXCR4 signaling (Busillo and Benovic 2007). In one study, the JAK/STAT pathway was
found to be activated after CXCL12 induces a transient association of JAK proteins with
CXCR4 and later the nuclear translocation of STAT proteins (Vila-Coro, RodriguezFrade et al. 1999). In another study, two non-visual arrestins, arrestin-2 and -3, were
reported to enhance CXCR4-mediated ERK activation by acting as scaffold proteins.
Further study by the same group reported that p38 activation can be dependent on
arrestin-3 activity following CXCL12 stimulation (Cheng, Zhao et al. 2000, Sun, Cheng et
al. 2002).

4.2 The role of CXCR4/CXCL12 axis in AML
While most AML patients achieve CR (defined by BM blast less than 5%) after
initial cytotoxic chemotherapy, long-term disease-free survival still remains low due to
subsequent relapse of disease (Mozafari, Moeinian et al. 2017). Bone marrow is thought
to be the primary site protecting leukemia cells and allowing them to escape the effects
of cytotoxic drugs. Thus, the BM microenvironment is important for resistance to
chemotherapy and relapse in AML (Burger and Kipps 2006). CXCR4 has been found to
be highly expressed in several subtypes of AML with important functional roles (Mohle,
Schittenhelm et al. 2000). CXCL12, constitutively produced by BM stroma, binds to
CXCR4 expressed on the surface of leukemia cells and leads to activation of multiple
downstream signaling pathways critical for the survival and proliferation of leukemia cells
(Cho, Kim et al. 2017).
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Evidence from both in vitro and in vivo studies has shown that CXCR4 regulates
the homing and retention of leukemia cells within the bone marrow. Mohel et
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Figure 1.5. CXCR4/CXCL12 signaling pathway.
CXCR4 specifically binds to CXC12. This interaction further elevates Calcium, activates
PI3K, ERK, and NF-κB pathways, which are important for cell growth, proliferation and
migration.
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al. and Burger et al. identified that CXCR4 expression induces leukemia cell chemotaxis
and migration beneath BM stromal cells (Mohle, Bautz et al. 1998, Burger, Spoo et al.
2003). More importantly, they observed that variations in the surface density of CXCR4
in AML influences CXCL12-guided migration (Mohle, Bautz et al. 1998). Studies by
several groups demonstrated that the BM stromal cells promote AML cell cycle arrest
and a decrease in cell division compared to leukemia cells that don’t migrate underneath
BM stromal cells (Burger, Spoo et al. 2003). In addition, preclinical and clinical data have
indicated that overexpression of CXCR4 is associated with poor prognosis in AML
patients, while low CXCR4 expression on AML cells correlated with a better prognosis
(Konoplev, Rassidakis et al. 2007, Spoo, Lubbert et al. 2007). Importantly, Sison et al.
reported that, in AML cell lines, there was an upregulation in CXCR4 expression upon
chemotherapy treatment that correlated with increased survival, as well as enhanced
migration toward CXCL12 (Sison, McIntyre et al. 2013).
These data suggest that CXCR4 is functionally important for AML cells even
though its expression level in AML is heterogeneous (Spoo, Lubbert et al. 2007). Thus,
disrupting the interaction between leukemia cells and bone marrow stroma by targeting
the CXCR4/CXCL12 interaction represents an attractive strategy to prevent drug
resistance and achieve better treatment outcomes for AML patients.

4.3 Inhibition of CXCR4 as therapeutic agents in AML
As mentioned above, the CXCR4/CXCL12 axis is important for AML cell survival,
making it a therapeutic target for AML. There have been different studies and clinical
trials focusing on interrupting the interaction between leukemia cells and BM
microenvironment by targeting the CXCR4/CXCL12 axis (Table 1.1).
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Table 1.1 Inhibitors for CXCR4 in AML
CXCR4
inhibitors
AMD3100
(Plerixafor)

BKT140
LY2510924

Application

References

Mobilizes leukemic blasts into the
peripheral blood, inhibit
proliferation and promote
differentiation of leukemia cells

Liesveld, Bechelli et al.
2007
Tavor, Eisenbach et al.
2008
Nervi, Ramirez et al. 2009
Beider, Begin et al. 2011
Zhang, Patel et al. 2012

Mobilizes cells into the circulation,
induce apoptosis and
differentiation, inhibit proliferation
Mobilizes cells into the circulation,
inhibit proliferation and induce
differentiation

Inhibits Calcium flux and migration
Ulocuplumab and induce apoptosis
PF-06747143

Promotes mobilization and induce
cell death

Cho, Zeng et al. 2015

Kuhne, Mulvey et al. 2013
Zhang, Saavedra et al.
2017
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AML cells in vitro and in vivo by mobilizing leukemic blasts into the circulation. One study
demonstrated that AMD3100 inhibited CXCL12-induced migration of AML cells,
decreased colony-forming ability, and affected AML engraftment into NOD/SCID mice
(Liesveld, Bechelli et al. 2007). AMD3100 was also shown to be capable of inhibiting
proliferation and inducing differentiation of AML cell lines, as well as enhancing the
chemosensitivity of leukemia cells to drugs without any anti-leukemia effects as a single
agent in vivo (Tavor, Eisenbach et al. 2008, Nervi, Ramirez et al. 2009). However, Tavor
et al demonstrated that AMD3100 treatment is able to decrease survival and cause
changes that mimic differentiation using human AML cell lines (Tavor, Eisenbach et al.
2008). One explanation for those contradictory results is that AMD3100 is a weak
CXCR4 antagonist and only inhibits growth or survival at a very high dose, which may
not be well tolerated by AML patients (Kuhne, Mulvey et al. 2013, Abraham, Klein et al.
2017).
In addition to small molecule CXCR4 inhibitors, some potent peptide inhibitors
have been identified and tested in different AML models (Oishi and Fujii 2012). 4Fbenzoyl-TN14003 (BKT140), a peptide CXCR4 inhibitor, was tested by Beider et al, and
their study demonstrated that BKT140 induced decreased cell survival through apoptosis
in the human AML cell line, NB4. They also found that BKT140 reduced tumor growth in
a subcutaneous xenograft in SCID/beige mice (Beider, Begin et al. 2011). A similar
study by Zhang et al. in 2012 found that BKT140 reduced cell growth and leukemia
burden in vitro and in vivo as a single agent (Zhang, Patel et al. 2012). Another peptide
CXCR4 inhibitor, LY2510924, was shown to be able to disrupt the CXCR4/CXCL12 axis
in AML cells and inhibit proliferation simultaneously. LY2510924 also caused the
mobilization of leukemic cells into the circulatory system, inhibiting multiple pro-survival
signals and inducing differentiation of leukemia cells using primary AML xenograft
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models. This study provided evidence that LY2510924 can exert anti-leukemia effects as
monotherapy (Cho, Zeng et al. 2015).
Using monoclonal antibodies to inhibit CXCR4 activity is another alternative
method to inhibit CXCR4. Kuhne et al. introduced a monoclonal antibody, Ulocuplumab
(BMD-936564), which specifically recognizes human CXCR4 and induces apoptosis in
AML cell lines, as well as exerting anti-leukemia activity in xenograft models of APL
(Kuhne, Mulvey et al. 2013).
Zhang et al. reported a new CXCR4 receptor antagonist IgG1 antibody, PF06747143, which binds strongly to both AML cell lines and primary AML cells and
inhibits the chemotaxis in response to CXCL12. In addition, administration of PF06747143 to patient-derived xenograft (PDX) models promoted the mobilization of AML
cells from BM niche into the circulatory system. In secondary transplantation from the
PDX models, PF-06747143 was shown to decrease re-grafting efficiency of AML cells,
implying that monoclonal antibody has an impact on LSC activity (Zhang, Saavedra et al.
2017).
In summary, these data demonstrate the importance of CXCR4/CXCL12 axis for
the maintenance of AML survival even without stroma and validate the potential
therapeutic benefits of CXCR4 antagonists in treating AML. In addition, the tested
CXCR4 antagonists cause similar effect on leukemia cells, implying that they are
capable of directly inhibiting the interaction between CXCR4 and CXCL12.

4.4 Polymeric CXCR4 antagonists (PCX)-mediated delivery of siRNA in
cancer
In the past decade, chemotherapy including cytarabine combined with an
anthracycline remains the standard treatment for AML patients (Briot, Roger et al. 2018).
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One characteristic of AML is the existence of critical genetic alterations during the
leukemogenesis. Small molecule inhibitors targeting those genetic abnormalities have
been developed in recent years, which have the potential to improve outcomes for AML
patients (Cunningham, Finckbeiner et al. 2012, Al-Hussaini and DiPersio 2014, Illendula,
Pulikkan et al. 2015, Illendula, Gilmour et al. 2016, Zhou and Chng 2018). However,
these inhibitors are unable to completely eliminate leukemia. Therefore, more effective
therapeutic strategies targeting those molecular events need to be developed.
As an alternative therapeutic approach for AML, RNA interference (RNAi) inhibits
gene expression or translation process by neutralizing the target mRNA molecules.
siRNA and microRNA (miRNA) are the key to the RNAi process, both of which are able
to knock down key oncogenes by targeting related mRNA expression (Lam, Chow et al.
2015). siRNA-based gene silencing can be used to deplete key oncoproteins important
for cancer cell growth and proliferation, as well as resistance to chemotherapy drugs.
siRNA is chemically synthesized double-stranded (ds) RNA containing 19-23 base pairs,
where 2 nucleotides are unpaired at the 5’-phosphorylated ends and unphosphorylated
3’ ends (Elbashir, Harborth et al. 2001). siRNA directly incorporates into the RNAinduced silencing complex (RISC) complex and discards the sense strand, leaving the
anti-sense strand, which is complementary to target mRNA. Subsequently, the antisense strand guides the active RISC to the target mRNA, leading to the cleavage of
mRNA by the endonuclease argonaute 2 (AGO2). As a result, the translation of target
mRNA is inhibited (de Fougerolles, Vornlocher et al. 2007). However, before entering
the target cells, there are some hurdles for siRNA to overcome, for example, a short-half
life, its negative charge leading to poor interaction with the cell membrane, as well as
endosomal escape in the acidic environment. Thus, suitable carriers are required for
improving siRNA’s therapeutic effects by gene silencing. Nanoparticle-mediated delivery
of siRNA has been explored recently as a reliable non-viral RNAi pathway (Wang,
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Kumar et al. 2016, Xie, Wang et al. 2018). Using nanoparticle delivery systems has
several advantages. For instance, the siRNAs tend to have prolonged half-lives with
improved pharmacokinetics (Babu, Muralidharan et al. 2016). Recently, a polymer that is
capable of carrying siRNA as well as inhibiting CXCR4 activity has been tested in
multiple cancer types (Li, Zhu et al. 2012, Wang, Kumar et al. 2016, Xie, Wang et al.
2018). The polymer derives from AMD3100 and is a cyclam-based polymeric CXCR4
antagonist (PCX). To date, PCX has been used to deliver siRNA/miRNA into different
types of cancer cells including pancreatic cancer and cholangiocarcinoma (Wang,
Kumar et al. 2016, Xie, Wang et al. 2018).
In summary, dual-function PCX/siRNA polyplexes can inhibit both CXCR4 activity
and deliver siRNA into cancer cells. As a result, this strategy can effectively regulate
tumor microenvironment, leading to decreased cancer progression as well as improved
cancer therapies. However, whether PCX or PCX/siRNA polyplexes can be used to
target AML cells has not be investigated. Examining the potential effects of PCX on
survival of AML cells will have potential as a novel treatment for AML.
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CHAPTER II
Materials and Methods
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5.1 Mice
Wild-type C57BL6/129SvEv mice (Taconic) were used as transplant recipients.
Gt(ROSA)26Sortm4(ACTB-tdTomato, -EGFP/Luo/J) were obtained from Jackson Laboratory, and
bred with Cbfb-MYH11+/56M, Mx1-Cre+ mice (Kuhn, Schwenk et al. 1995, Kuo, Landrette
et al. 2006, Muzumdar, Tasic et al. 2007). Mice were housed under specific pathogenfree conditions and sacrificed for analysis at the indicated times. Mice were genotyped
by polymerase chain reaction (PCR) using tail-snip DNA, as described previously
(Muzumdar, Tasic et al. 2007, Hyde, Kamikubo et al. 2010, Hyde, Zhao et al. 2015).
Mice were treated with a single 200 µg dose of polyinosine-polycytidylic acid (pIpC) by
intraperitoneal injection to induce Cbfb-MYH11 expression, and monitored for leukemia
development, as described previously (Hyde, Kamikubo et al. 2010, Hyde, Zhao et al.
2015). Transplantation was performed by retro-orbital injection into sub-lethally irradiated
congeneic recipients (600 cGy, 1-2 hours prior to transplantation). Recipient mice were
monitored daily for any abnormal behavior or physiologic changes. Leukemia
development was monitored up to one year. Mice were sacrificed at signs of sickness,
and leukemia cells from bone marrow or spleen were collected and cryopreserved in
10% dimethyl sulfoxide (DMSO). Doxorubicin (Pfizer, Bentley, WA, Australia) was
reconstituted with phosphate-buffered saline (PBS) and filtered. Leukemic mice were
administered an intraperitoneal injection of 2 mg/kg doxorubicin and sacrificed 48 hours
later. Doxycycline (2 mg/mL, DOX, Clontech, Mountain View, CA) was added to drinking
water that contained 5% sucrose. Untreated mice were provided with 5% sucrose
drinking water as a control. All animals used and the procedures performed in this study
were approved by the University of Nebraska Medical Center Institutional Animal Care
and Use Committee.
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5.2 Cell culture
Mouse leukemia cells were isolated from the spleens of sick animals and were
cultured in RPMI 1640 (ATCC), supplemented with 20% fetal bovine serum (FBS) ESQualified (Life Technologies, Eugene, OR, USA), 2 mM L-glutamine, and 1% penicillinstreptomycin. Medium was supplemented with cytokines at the indicated concentration:
10 ng/mL IL-3 (Peprotech, Rocky Hill, NJ, USA), 10 ng/mL IL-6 (Peprotech), 20 ng/mL
SCF (Peprotech). For in vitro treatment with cytokines and blocking antibody, IL-33
(Peprotech) was used at 100 ng/mL, and anti-IL1RL1 antibody (R&D systems,
Abingdon, UK) was used at 1 µg/mL. Kasumi-1 cell line was purchased from the ATCC
and maintained in RPMI-1640 (ATCC) supplemented with 20% FBS, 2 mM L-glutamine
and 1% penicillin-streptomycin. OP-9 cells were cultured in α-MEM (Gibco, Grand
Island, NY, USA) with 20% FBS. GFP+ mouse leukemia cells were cultured on a
confluent layer of irradiated OP-9 cells in medium supplemented with 57 µM βmercaptoethanol. HEK293T cells were maintained in DMEM medium (Corning,
Manassas, VA, USA) supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillinstreptomycin. Colony-forming assays were performed using 104 cells per mL in 6-well
plate equal numbers of leukemia cells suspended in Methocult 3434 (StemCell
Technologies , Vancouver, BC, Canada) according to the manufacturer’s protocol. The
leukemia cells used were non-GFP and from three independent Cbfb-MYH11+/56M, Mx1Cre+ mice. After 14 days in culture, plates were scored for colony number (both dense
and sparse colonies) and replated as indicated. All cells were cultured in a 37º C
humidified atmosphere containing 5% CO2. No cell line authentication was performed by
the authors. Cells were routinely tested for mycoplasma (Mycoalert Plus, Lonza, Basel,
Switzerland). All experiments involving cell lines were performed at least 3 independent
times.
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5.3 RNA isolation and real-time RT-PCR
Total RNA was isolated from cells using Trizol reagent (Invitrogen), according to
the manufacturer’s specifications, synthesized into cDNA using reverse transcription
PCR (GE Health) or EcoDry Premix (Clontech). Quantitative real-time PCR analysis
(qRT-PCR) was performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo
Fisher Scientific, Rockford, IL, USA) with specific primers for Human RUNX1, Mouse
Runx1, Actb (mouse)/ACTB (human), Bcl-xl, Bcl-2, TRAF-1, TRAF-2, Mcl-1, and
GAPDH (Integrated DNA Technologies). The real-time PCR was run in a StepOnePlus
Real-Time PCR System (Invitrogen). Expression levels of genes were normalized to
Actb/ACTB mRNA or GAPDH mRNA. Primer sequences for Bcl-xl, Bcl-2, TRAF-1,
TRAF-2, Mcl-1, Actb/ACTB, Runx1/RUNX1 were described previously (Sekeres 2008,
Kuo, Zaidi et al. 2009, Xiang, Luo et al. 2010, Medearis, Han et al. 2011, Ben-Ami,
Friedman et al. 2013). Cbfb-MYH11 primer sequences: forwardCCAGCAAGCTGAGGAGCGGCG, reverse-TGACGGTGACCAGAGTG.

5.4 PCR for Cbfb-flMYH11 excision efficiency
DNA was isolated from sorted cells with the DNeasy Blood & Tissue Kit
(QIAGEN, Hilden, Germany), according to the manufacturer’s instructions. Excision of
Cbfb-flMYH11 was determined using primers that amplify both the excised allele and the
unexcised allele. Primer sequences for the unexcised allele: forwardCCAGCAAGCTGAGGAGCGGCG, reverse-TGACGGTGACCAGAGTG. Primer
sequences for the excised allele: forward-TGCCAGAACAGAATGGAACA, reverseCGGGAGTGGTGGTGTACTTT. Primer sequences for normalization: forwardCCCACTGTGTGCATTCCAGATTGG, reverse-GACGGTGATGGTCAGAGTGAAGC.
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5.5 Lentiviral production and transduction
HEK293T cells were transfected with third-generation lentiviral plasmids, which
coexpress GFP or DsRed. The viral supernatant was collected 48 hours posttransfection. For transduction, mouse leukemic spleen cells were incubated with viral
supernatant, supplemented with cytokines as described above with the addition of 8
μg/mL polybrene. Cells were spinfected at 2,000 rpm for 90 minutes, followed by a 6hour incubation and a second spinfection. At 48 hours after the start of transduction,
cells were sorted using the GFP or DsRed signal.

5.6 FACS staining and sorting
Lineage-negative pre-leukemic cells were isolated from the bone marrow of
pIpC-treated mice using the EasySep™ negative selection mouse hematopoietic
progenitor enrichment cocktail (StemCell Technologies) according to the manufacturer’s
instructions. Cells were stained with PE-conjugated anti-CSF2RB (BD Pharmingen,
Oxford, UK), PER-CP5.5-conjugated anti-IL1RL1 (BioLegend, San Diego, CA), and APC
conjugated anti-KIT (BD Biosciences). For transplantation studies of sorted LSC subpopulations, mouse leukemia cells isolated from the spleens of sick mice were stained
with PE-conjugated anti-CSF2RB (BD Pharmingen). CSF2RB− cells were enriched and
selected on an autoMACS Pro Separator (Miltenyi, Auburn, CA) using PE-microbeads
and column per manufacturer’s instructions. Cells were further stained with APC
conjugated anti-KIT (BD Biosciences) and PER-CP5.5-conjugated anti-IL1RL1
(BioLegend). Cellular viability was determined by staining with 4′,6-diamidino-2phenylindole (DAPI). Cell proliferation was determined by BrdU incorporation using the
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BrdU Flow Kit (BD Pharmingen) according to the manufacturer’s instructions. Cells were
pulse labeled with BrdU for 1 hour, and mice were sacrificed 1 hour afer a single BrdU
injection. Cell cycle was determined by propidium iodide (PI) staining afer cells were
fxed with 70% ethanol. BV421-conjugated anti-Mac-1 (BD Biosciences) and BV510conjugated anti-Gr-1 (BD Biosciences) were also used for FACS analysis. To strip the
cells of cell surface proteins, cells were incubated with acid stripping buffer (0.5% acetic
acid, 4 M NaCl, pH 3.0) to remove any surface-bound and non-internalized antibody.
Cells were analyzed using BD LSRII flow cytometer (BD Biosciences) and sorted using
BD FACSAria (BD Biosciences) equipped with FACSDiva sofware (Becton Dickinson,
San Jose, CA, USA). FACS data were analyzed by FlowJo sofware (Tree Star, Ashland,
OR, USA) and ModFit sofware (Verity Sotfware, Topsham, ME).

5.7 Histological staining
Cells were affixed to Surgipath Apex Superior Adhesive Slides (Leica
Microsystems, Weztlar, Germany) using a Shandon Cytospin III cytocentrifuge for 5
minutes at 800 rpm. Slides were stained using Protocol Hema 3 Wright-Giemsa stain
(Thermo Fisher Scientific) according to the manufacturer’s protocol and were examined
using an Olympus BX51 microscope at 100X magnification.

5.8 Western blot
Mouse leukemia cells were lysed with RIPA buffer (50 mM Tris-HCl pH 8.0, 150
mM NaCl, 1% Triton, 0.5% deoxycholate, and 0.1% SDS), supplemented with a
protease inhibitor (Roche, Penzberg, Germany). Samples were run on 4-12% Bis-Tris
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gel (Invitrogen), transferred to PVDF membrane (NOVEX, San Diego, CA, USA). The
membrane was incubated with the primary antibody in 5% bovine serum albumin (BSA)
overnight, followed by 1-hour incubation with horseradish peroxidase (HRP)-conjugated
anti-rabbit or anti-mouse secondary antibodies at room temperature, washed and
incubated with chemiluminescence (ECL) reagent (Thermo Fisher Scientific) and then
exposed to film. Densitometric analysis was performed using Image J software (National
Institutes of Health, Bethesda, MD, USA). The relative protein level was normalized to
the corresponding protein level. A list of primary and secondary antibodies used can be
found in Table 2.1.
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Table 2.1 List of antibodies, manufacturer, catalog number, and dilutions used for
western blot
Antibody

Manufacturer

Catalog
Number

Dilutions

SMMHC (MYH11)

Novus Biologicals

21370002

1:10,000

GAPDH

Ambion

AM4300

1:40,000

TRAF-1

Santa Cruz

sc-6253

1:500

Mcl-1

Santa Cruz

sc-819

1:1,000

RUNX1

Active Motif

39000

1:1,000

Bcl-xl

Santa Cruz

sc-8392

1:500

ERK

Santa Cruz

sc-94

1:1,000

pERK (p42/p44)

Cell Signaling

9101S

1:1,000

AKT

Cell Signaling

563040

1:1,000

pAKT (s472)

Cell Signaling

4060S

1:1,000

Anti-mouse secondary

Vector
Laboratories

PI-2000

1:10,000

Anti-rabbit secondary

Vector
Laboratories

PI-1000

1:10,000
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5.9 Synthesis of PCX
Cholesterol-modified polymeric CXCR4 inhibitors PCX (Mw = 16.7 kDa, Mw/Mn =
1.9, cholesterol wt% = 16.8%) were synthesized and characterized as previously
described (Wang, Kumar et al. 2016). Succinimidyl ester of Alexa Fluor® 647 carboxylic
acid was obtained from Life Technologies (Eugene, OR, USA). Alexa Fluor 647-labeled
PCX polymers (AF647-PCX) were prepared according to the manufacturer’s instructions
and purified by dialysis to remove unreacted free dye. Non-targeting siRNA control
(siNC, 5’-UCACAACCUCCUAGAAAGAGUAGA-3’), human RUNX1 siRNA (siRUNX1,
5’-GACAUCGGCAGAAACUAGAUU-3’), and cholesterol-modified mouse Runx1 siRNA
(siRunx1, 5’-GCACCUACCAUAGAGCCAUCAACUU-3’) were purchased from
Dharmacon (Dharmacon, Inc., Chicago, IL, USA). Human RUNX1 siRNA sequence has
been described previously (Ben-Ami, Friedman et al. 2013).

5.10 Preparation and characterization of nanoparticles
The capability of PCX polymer to condense siRNA was analyzed by
electrophoresis in a 2% agarose gel which contained 0.5 μg/mL ethidium bromide (EtBr).
The preparation of PCX/siRNA nanoparticles was performed by adding a predetermined
volume of PCX solution to an siRNA solution (20 μM in 10 mM HEPES pH 7.4) to
achieve the desired polycation-to-siRNA w/w ratio and vortexing for 10 s. Nanoparticles
were further incubated at room temperature for 20 min. Nanoparticles were then loaded
(20 μL of the sample containing 0.5 μg of siRNA) into gel wells and run for 20 min at 100
V in 0.5 × Tris/Borate/EDTA (TBE) buffer. The gels were visualized under UV
illumination with a KODAK Gel Logic 100 imaging system. Hydrodynamic diameter and
zeta potential of the nanoparticles were measured by dynamic light scattering (DLS)
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using a ZEN3600 Zetasizer Nano-ZS (Malvern Instruments Ltd., Malvern,
Worcestershire, UK). The morphology of nanoparticles was observed under
transmission electron microscopy (TEM, Tecnai G2 Spirit, FEI Company, Houston, TX,
USA) using NanoVan® negative staining (Nanoprobes, Yaphank, NY, USA). The
release of siRNA from nanoparticles was analyzed by 320 heparin displacement assay.
Nanoparticles (w/w = 2) were incubated with increasing concentrations of heparin
solution for 30 min at room temperature. The samples were then analyzed by agarose
gel electrophoresis.

5.11

Statistical analysis
The Kaplan-Meier curves of overall survival (OS) were plotted, and log-rank

(Mantel-Cox) test was performed by Graph Pad Prism 7 for Windows (Graph Pad
Software, La Jolla, CA, USA) or SPSS software (SPSS, Chicago, IL, USA). Data are
represented as mean values ± standard deviation. The significance of difference was
analyzed using either the Student t test in Excel or ANOVA with Tukey post-hoc test
(Graph Pad Software Inc.), as appropriate and indicated in the figure legends. P values
<0.05 were considered statistically significant. The LSC frequency was calculated and
plotted using ELDA software (bioinf.wehi.edu.au/software/elda/) (Hu and Smyth 2009,
Shlush, Zandi et al. 2014, Allemani, Weir et al. 2015).
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CHAPTER III
IL1RL1 is dynamically expressed on Cbfb-MYH11+
leukemia stem cells and promotes cell survival

Data from this chapter were published in Scientific Reports, 2019 Feb 11;9(1):1729.
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6 Abstract
Acute myeloid leukemia (AML) is often characterized by the presence of specific,
recurrent chromosomal abnormalities. One of the most common aberrations, inversion of
chromosome 16 [inv(16)], generates the fusion oncogene CBFB-MYH11. Previously, we
used a mouse knock-in model to show that Cbfb-MYH11 induces changes in gene
expression and results in the accumulation of abnormal myeloid cells, a subset of which
are enriched for leukemia stem cell (LSC) activity. One gene upregulated by CbfbMYH11 encodes the cytokine receptor IL1RL1 (ST2). IL1RL1 and its ligand IL-33 are
known regulators of mature myeloid cells, but their roles in AML are not known. Here, we
use Cbfb-MYH11 knock-in mice to show that IL1RL1 is expressed by cell populations
with high LSC activity, and that the cell surface expression of IL1RL1 is dynamic,
implying that the expression of IL1RL1 is not restricted to a specific stage of
differentiation. We also show that treatment with IL-33 increased serial replating ability
and expression of pro-survival proteins in vitro. Finally, we show that IL1RL1+ cells can
survive chemotherapy better than IL1RL1- cells based on in vivo study. Collectively, our
results indicate that IL1RL1 is dynamically expressed in Cbfb-MYH11+ leukemia cells
and has an important role for their survival.

7 Introduction
Acute myeloid leukemia (AML) is a hematopoietic malignancy often
characterized by the presence of specific, recurrent chromosomal abnormalities
(Takahashi 2011). One of the most common aberrations is inversion of chromosome 16
[inv(16)], which generates a fusion between the transcription factor gene, CBFB, and the
gene for smooth muscle myosin heavy chain, MYH11 (Liu, Seidel et al. 1994, Liu, Hajra
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et al. 1995). Expression of CBFB-MYH11 which encodes the fusion protein CBFβSMMHC, is the initiating event in inv(16) AML, but additional cooperating mutations are
required for transformation to a frank leukemia. Common cooperating mutations include
activating mutations in receptor kinases, including KIT and fms like tyrosine kinase 3
(FLT3), or small GTPases like RAS (Boissel, Leroy et al. 2006, Haferlach, Dicker et al.
2010, Zhao, Melenhorst et al. 2012, Paschka, Du et al. 2013, Xue, Pulikkan et al. 2014).
Although considered a prognostically favorable subtype of AML, approximately 50% of
patients with inv(16) AML relapse and eventually die of their disease (Marcucci, Mrozek
et al. 2005, Appelbaum, Kopecky et al. 2006, Bhatt, Kantarjian et al. 2013, Brunner,
Blonquist et al. 2014). This is likely due to the persistence of leukemia stem cells (LSCs).
LSCs are thought to be a small minority of cells that reside at the apex of a hierarchical
differentiation scheme in leukemia and can both self-renew and generate non-selfrenewing progenitor-like cells. LSCs are also thought to be mostly quiescent, allowing
them to evade conventional chemotherapies which target primarily proliferating cells
(Ishikawa, Yoshida et al. 2007, Gentles, Plevritis et al. 2010, Kreso and Dick 2014,
Thomas and Majeti 2017).
Previously, a knock-in mouse model of inv(16) AML was established in which a
conditional allele of Cbfb-MYH11 is expressed from the endogenous Cbfb locus
(Cbfb+/56M) (Kuo, Landrette et al. 2006, Hyde, Zhao et al. 2015). We showed that
expression of Cbfb-MYH11 leads to changes in gene expression and an abnormal
process of differentiation that culminates in a population of abnormal, immature myeloid
cells expressing the cytokine receptor CSF2RB (Kuo, Landrette et al. 2006, Hyde,
Kamikubo et al. 2010). Using in vivo transplantations, we found that the presumably
more immature, CSF2RB- cells are enriched for LSC activity. We also identified a
second cytokine receptor, IL1RL1 (ST2), which is highly expressed in Cbfb-MYH11
expressing cells in both the CSF2RB- and CSF2RB+ populations (Hyde, Kamikubo et al.
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2010). This raises the possibility that IL1RL1 could be expressed on LSCs and/or play a
functional role in regulating their activity.
IL1RL1 is an IL-1 type receptor that is expressed on a subset of T cells and
different types of mature myeloid cells, including mast cells, eosinophils, basophils,
neutrophils and macrophages (Griesenauer and Paczesny 2017, Cayrol and Girard
2018, Dinarello 2018). IL1RL1’s only known ligand is the cytokine IL-33. Binding of IL-33
to IL1RL1 on normal myeloid cells triggers a pro-inflammatory response, which can
involve the release of additional cytokines, increased proliferation, and/or a block in
apoptosis. Recent studies suggest that the IL1RL1/IL33 pathway may be involved in
malignant hematopoiesis as well. IL1RL1 is upregulated in chronic myeloid leukemia
cells (CML) by the fusion protein BCR-ABL and treatment with IL-33 promotes
resistance to the BCR-ABL inhibitor imatinib (Levescot, Flamant et al. 2014). In addition,
IL1RL1/IL-33 signaling exacerbates dysregulated myelopoiesis in mouse models of
myeloproliferative neoplasms (MPN) (Mager, Riether et al. 2015); however, its role in
AML has not yet been demonstrated.
In the present study, we show that expression of the leukemogenic fusion gene
Cbfb-MYH11 induces expression of IL1RL1 prior to CSF2RB, implying that IL1RL1
marks an earlier stage of leukemia development. Thus, we tested whether IL1RL1, in
conjunction with the hematopoietic stem/progenitor marker KIT, can be used to further
enrich for LSCs in the CSF2RB- population. Using limiting dilution transplantation assay
(LDA), we found that CSF2RB- IL1RL1- KIT+, CSF2RB- IL1RL1+ KIT+, and CSF2RBIL1RL1+ KIT- cells showed considerable LSC activity in vivo. We also found that the rate
of leukemia development correlated with the proliferation rate of each sub-population.
Interestingly, we found that, regardless of the sub-population tested, the resultant
leukemia had an immunophenotype similar to the original leukemia sample. We also
show that activation of IL1RL1 signaling by IL-33 enhanced serial replating ability, while

49

decreasing apoptosis and increasing viability. Finally, our preliminary data indicates that
KIT expression cooperates with IL1RL1 in reducing apoptosis and inducing proliferation.
Based on these findings, we propose that IL1RL1 cell surface expression is dynamic and
contributes to leukemia cell survival.

8 Results
8.1 Expression of Cbfb-MYH11 induces abnormal expression of IL1RL1
We showed previously that the expression of Cbfb-MYH11 causes an abnormal
differentiation process that culminates in cells expressing CSF2RB, and that the less
differentiated CSF2RB- population is enriched for LSCs (Hyde, Kamikubo et al. 2010).
Another cell surface marker upregulated by Cbfb-MYH11 is IL1RL1. To examine if
IL1RL1 could be a marker for less differentiated leukemia cells, we characterized the
expression of IL1RL1 after induction of Cbfb-MYH11+ but before leukemia development.
We used mice expressing a conditional allele of full-length Cbfb-MYH11 (Cbfb+/56M)
paired with the inducible Mx1-Cre transgene (Kuo, Landrette et al. 2006). Cbfb+/+, Mx1Cre+ mice were used as control. Mice were treated with polyinosinic-polycytidylic acid
(pIpC) to induce the expression of Cbfb-MYH11, and sacrificed on days 4, 7, 10, and 20
post-treatment. The lineage negative (lin-) bone marrow cells were stained for CSF2RB,
IL1RL1, and the hematopoietic stem/progenitor cell marker KIT expression (Figure
3.1a). We found that Cbfb-MYH11 led to a significant increase of CSF2RB- IL1RL1+ cells
starting from day 4, as compared to control mice. Starting on day 7, we observed a
smaller population of IL1RL1, CSF2RB double positive (CSF2RB+ IL1RL1+) cells, and
this population continued to increase through day 20, but did not reach statistical
significance as compared to the control mice (Figure 3.1b,c). We did not observe

50

changes in the expression of KIT from leukemic Cbfb-MYH11+/56M, Mx1-Cre+ mice as
compared to control mice (Figure 3.2a,b). To test if Cbfb-MYH11 expression correlates
with the abnormal cell surface marker expression, we examined the expression of CbfbMYH11 in the lin- bone marrow cells collected at 4, 7, and 10 days after pIpC treatment.
We found that Cbfb-MYH11 was expressed at day 4 and its expression increased even
further at day 7 (Figure 3.3), consistent with previous work (Hyde, Zhao et al. 2015).
This indicates that the changes in IL1RL1 and CSF2RB coincide with detectable
expression of Cbfb-MYH11. Collectively, these results indicate that Cbfb-MYH11
induces a population of CSF2RB- IL1RL1+ first, which is followed by a population of cells
expressing both markers. Our findings imply that IL1RL1 is associated with a population
of cells at an earlier stage in the abnormal differentiation process induced by CbfbMYH11.
To determine whether IL1RL1 continues to be expressed in the LSC-enriched
CSF2RB- population after leukemic transformation, we stained leukemia cells isolated
from Cbfb+/56M, Mx1-Cre+ mice for IL1RL1 and KIT. We found that the majority of
leukemic CSF2RB- cells express both IL1RL1 and KIT (Figure 3.4a,b).
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Figure 3.1. Dysregulated expression of cell surface marker expression by CbfbMYH11.
(a) Schematic representation of experimental design. Cbfb+/56M; Mx1-Cre+ or Cbfb+/+;
Mx1-Cre+ mice were injected with polyinosinic-polycytidylic acid (pIpC) to induce the
expression of Cbfb-MYH11. Bone marrow cells were harvested, lineage-negative (lin-)
cells isolated, and stained with antibodies for IL1RL1 and CSF2RB.
(b) Representative FACS plots showing the expression of CSF2RB and IL1RL1 at the
indicated time points after the induction of Cbfb-MYH11.
(c) Bar graph showing the percentages (%) of CSF2RB- IL1RL1+ (left) and CSF2RB+
IL1RL1+ (right) cells at the indicated time points. N≥3. **P<0.01.
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Figure 3.2. The expression of KIT after pIpC treatment.
(a) Representative FACS plots showing the expression of KIT and IL1RL1 at the
indicated time points after the induction of Cbfb-MYH11.
+

(b) Bar graph showing the percentages (%) of KIT cells at the indicated time points.
N≥3.
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(b) Bar graph of IL1RL1 and KIT expression in CSF2RB- population. N≥3. ****P<0.0001.
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8.2 CSF2RB- sub-populations have different LSC activities in vitro and in
vivo
The observations that Cbfb-MYH11 induces IL1RL1 earlier than CSF2RB, and
that IL1RL1 is expressed on the majority of leukemic CS2FRB- cells, raise the possibility
that IL1RL1 can be used to further isolate LSCs. Before testing this, we confirmed that
the leukemic CSF2RB- population is enriched for colony-forming cells in vitro. We sorted
leukemic cells isolated from 3 independent Cbfb+/56M, Mx1-Cre+ mice and performed
colony-forming assays using equal numbers of CSF2RB+ and CSF2RB- cells. We found
that the CSF2RB- cells produced significantly more colonies than did the CSF2RB+ cells,
consistent with our previous in vivo results (Hyde, Kamikubo et al. 2010) (Figure 3.5a).
Next, we tested whether IL1RL1 expression can further isolate LSCs. We found that the
CSF2RB- IL1RL1- cells formed significantly more colonies than did CSF2RB- IL1RL1+
cells, implying that LSCs are enriched within the CSF2RB, IL1RL1 double-negative
(CSF2RB- IL1RL1-) population (Figure 3.5b). Finally, we tested whether the
hematopoietic stem and progenitor marker KIT can further enrich for LSCs. We found
that significantly more colonies formed from CSF2RB- IL1RL1- KIT+ cells compared to
CSF2RB- IL1RL1- KIT- cells (Figure 3.5c). To test whether the different populations gave
rise to colonies with different phenotypes, we examined both the morphology and cell
surface marker expression of the colonies that arose from each population. We found
that colonies derived from the CSF2RB- and CSF2RB+ populations had similar
morphological appearance and gave rise to both CSF2RB- and CSF2RB+ cells (Figure
3.5d,e). Interestingly, the colonies from CSF2RB-, IL1RL1-; CSF2RB-, IL1RL1+;
CSF2RB-, IL1RL1-, KIT-; and CSF2RB-, IL1RL1-, KIT+ sorted cells all gave rise to cells
with similar immunophenotypic diversity (Figure 3.5e). This finding implies that, despite
the differences in colony-forming ability, the populations defined by CSF2RB, IL1RL1,
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and KIT may not be arranged in a strict hierarchical differentiation scheme. To determine
if the colonies we observed may be due to non-leukemic, healthy spleen cells, we sorted
spleen cells from wild-type mice into CSF2RB- IL1RL1- KIT+ and CSF2RB- IL1RL1- KITpopulations and plated the same number of cells as above in methylcellulose. We found
that only the wild-type CSF2RB- IL1RL1- KIT+ cells grew on methylcellulose, but they did
not give rise to the distinct colonies seen with leukemic cells (data not shown).
Collectively, these results indicate that the CSF2RB- IL1RL1- KIT+ population has
increased colony-forming ability in vitro, but that each population gives rise to colonies
with similar immunophenotypic and morphological characteristics.
To test whether IL1RL1 and KIT can be used to isolate cells with LSC activity in
vivo, we performed LDA using leukemia samples from three independent Cbfb-MYH11
expressing mice. Leukemia cells were then stained for CSF2RB, IL1RL1, and KIT, and
sorted into five sub-populations: CSF2RB- IL1RL1- KIT+, CSF2RB- IL1RL1+ KIT+,
CSF2RB- IL1RL1- KIT-, CSF2RB- IL1RL1+ KIT-, and CSF2RB+. To examine the sorting
purity, we analyzed the surface marker expression of each sorted sub-population
immediately after isolation via FACS. The purity in each sorted sub-population was more
than 90% (Figure 3.6a,b). 100, 1000, or 10,000 cells from each sorted sub-population
were transplanted, and recipient mice were monitored for leukemia development (Figure
3.6c). With the exception of CSF2RB- IL1RL1- KIT- cells, we found that each subpopulation caused leukemia at both the 1,000 and 10,000 cell doses, indicating that
each of these sub-populations contains LSCs. Mice transplanted with the CSF2RBIL1RL1+ KIT+ cells showed the shortest average life span and highest penetrance of
leukemia development with statistically significant differences in survival as compared to
mice transplanted with CSF2RB-, IL1RL1-, KIT+/-, or CSF2RB+ cells at the 10,000 cell
dose. Mice transplanted with CSF2RB- IL1RL1- KIT- cells had the longest time to
leukemia development and the lowest penetrance with statistically significant differences
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in survival as compared to mice transplanted with CSF2RB-, IL1RL1-, KIT+/- cells at the
10,000 cell dose (Figure 3.7a and Table 3.1). Interestingly, the CSF2RB-, IL1RL1-, KIT+
populations that showed enriched colony-forming ability in vitro, showed intermediate
LSC activity in vivo. Based on these results, the CSF2RB- IL1RL1+ KIT+ sub-population
was calculated to contain the highest frequency of LSCs, which was between 10- and
100-fold higher than the other sub-populations, followed by CSF2RB- IL1RL1+ KIT- cells,
and the CSF2RB- IL1RL1- KIT- the lowest (Figure 3.7b). The data suggests that
CSF2RB- IL1RL1+ cells are enriched for LSCs, especially those that are also expressing
KIT. This is in contrast to our in vitro colony assay results and thus suggests that colonyforming ability does not strictly correlate with LSC activity in vivo.
To determine if the different sorted sub-populations cause leukemia with similar
immunophenotypes, we performed cell surface staining on the leukemia cells from
recipient mice. We observed that the expression of CSF2RB, IL1RL1, and KIT in
recipient leukemia samples was similar to that of the original, donor leukemia samples,
regardless of the sub-population transplanted (Figure 3.7c). In addition, histological
examination of blood smears from transplanted mice showed no differences in blast
morphology (Figure 3.7d). This result demonstrates that the different LSC subpopulations recapitulate the phenotypic diversity of the original sample, which is one of
the defining criteria of LSCs.
One possible explanation for the unexpected finding that the CSF2RB-, IL1RL1-,
KIT+ population was not the most enriched for LSCs, is that some of these sorted subpopulations are contaminated with different numbers of non-leukemic, healthy spleen
cells. Two of the samples used for this analysis were derived from Cbfb+/56M, Mx1-Cre+
mice that also express carry a transgene (Gt(ROSA)26Sortm4(ACTB-tdTomato, -EGFP/Luo/J or
GFP+) that expresses green fluorescent protein (GFP) after Cre excision (Cbfb+/56M, Mx1Cre+, GFP+). Because non-leukemic cells that undergo Cre excision are unlikely to
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persist for the 5-6 months required for leukemia development, GFP expression can be
used to distinguish leukemic cells from normal, healthy cells in this model. Using these
mice, we found that the sub-population with the lowest percentage of GFP+ cells was the
CSF2RB- IL1RL1- KIT- population (average 92%, +/-11.3), with all other populations
above 98% GFP+ (Figure 3.8). We also stained the spleen cells from wild type mice for
CSF2RB, IL1RL1 and KIT and found that the majority of cells are negative for the three
markers (CSF2RB- IL1RL1- KIT-) (Figure 3.9a,b), which is consistent with our finding
that this population contains the most non-leukemic, healthy cells. These results indicate
that the only sub-population likely to contain significant numbers of non-leukemic,
healthy cells is the CSF2RB- IL1RL1- KIT-, and that differences in LSC frequencies in the
other populations is unlikely to be affected by normal spleen cells. To examine whether
the differences in behavior among the different LSC sub-populations could be due to
differences in Cbfb-MYH11 expression, we performed RT-PCR for the fusion gene on
sorted leukemia cells and found that that there is no significant difference in the
expression of Cbfb-MYH11 among each of the sorted sub-populations (Figure 3.10).
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Figure 3.5. Colony-forming cells are enriched in the CSF2RB-, IL1RL1-, KIT+
population.
(a-c) Bar graphs showing the relative number of colonies observed from leukemic cells
from 3 independent Cbfb+/56M; Mx1-Cre+ mice sorted for the indicated cell surface
markers.
(d) Representative photomicrographs of methylcellulose colonies derived from CSF2RBand CSF2RB+ cells after 14 days of culture are shown. Scale bar:100 μm.
(e) Bar graph showing the percentage of each sub-population in colonies observed from
leukemic cells from 3 independent Cbfb+/56M; Mx1-Cre+ mice sorted for the indicated cell
surface markers. N≥3. *P<.05; ****P<0.0001.
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Figure 3.6. Sorting strategy and post-sort analysis of each sub-population.
(a) Mouse leukemia cells were stained with anti-CSF2RB, anti-IL1RL1, and anti-KIT
antibodies. Each sub-population was then sorted on a BD FACS Aria. Dot
plots quantitate percentages of cells shown in each gate.
(b) Representative FACS plots of post-sort analysis of the sorted sub-populations. The
purity was greater than 90%. Data are from one of the three independent experiments.
(c) Schematic representation of experimental design. Leukemia cells from 3 independent
Cbfb-MYH11+/56M, Mx1-Cre+ mice were stained for CSF2RB, IL1RL1, and KIT and sorted
into the indicated sub-populations.
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Figure 3.7. Multiple sub-populations have LSC activity in vivo.
(a) Kaplan-Meier survival curves of mice transplanted with indicated number of cells
from the indicated sub-populations.
(b) Estimated frequency of LSCs and confidence interval for the indicated subpopulations.
(c) Bar graph showing the percentage of each sub-population in the original leukemia
sample, and in recipient mice transplanted with the indicated sub-population. For the logrank test P-values see Table 3.1.
(b) Representative Wright-Giemsa staining of peripheral blood smears from mice
transplanted with the indicated LSC sub-populations. Scale bar: 20 μm.
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Table 3.1. Differential survival in mice transplanted with different LSC sub-populations.

P value (Log-rank test)
Statistical differences between sub-populations
100 cells

1,000 cells

10,000 cells

-

-

+

-

+

+

0.7332

0.0547

0.0073 **

-

-

+

-

-

-

0.0652

0.0625

0.2336

CSF2RB- IL1RL1- KIT+ vs. CSF2RB- IL1RL1+ KIT-

0.4913

0.3272

0.1997

CSF2RB IL1RL1 KIT vs. CSF2RB

0.0652

0.6058

0.8843

CSF2RB- IL1RL1+ KIT+ vs. CSF2RB- IL1RL1- KIT-

0.0272*

0.0008***

<0.0001****

CSF2RB- IL1RL1+ KIT+ vs. CSF2RB- IL1RL1+ KIT-

0.2287

0.3807

0.1262

CSF2RB- IL1RL1+ KIT+ vs. CSF2RB+

0.0272*

0.0234*

0.0075**

CSF2RB- IL1RL1- KIT- vs. CSF2RB- IL1RL1+ KIT-

0.1451

0.0101*

0.0257*

CSF2RB IL1RL1 KIT vs. CSF2RB

>0.9999

0.1451

0.255

CSF2RB- IL1RL1+ KIT- vs. CSF2RB+

0.1451

0.1369

0.1737

CSF2RB IL1RL1 KIT vs. CSF2RB IL1RL1 KIT
CSF2RB IL1RL1 KIT vs. CSF2RB IL1RL1 KIT

-

-

-

-

+

-

+

+

Survival differences between groups were compared using the log-rank (Mantle-Cox)
test. P-values for pairwise comparisons of LSC sub-populations were indicated. N=9. *P
<0.05; **P <0.01; ***P<0.001; ****P<0.0001.
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8.3 LSC sub-populations have different rates of proliferation and
sensitivities to chemotherapy
In our transplantation study, we observed that the time taken to fatal leukemia
development and leukemia penetrance was different among the LSC sub-populations,
which may indicate a difference in proliferation rates, in addition to LSC frequency. To
test this, we used leukemia cells from Cbfb+/56M, Mx1-Cre+ mice that also express green
fluorescent protein (GFP), either from a lentivirus or from a transgene in the Rosa26
locus (Cbfb+/56M, Mx1-Cre+, GFP+). Mice were transplanted with GFP+ leukemia cells,
monitored for leukemia development, and treated with bromodeoxyuridine (BrdU) prior to
sacrifice. Cells from bone marrow and spleen were harvested and stained for cell
surface markers, as well as BrdU incorporation. We found that the CSF2RB- IL1RL1+
KIT+ population had the highest BrdU incorporation rate, which correlated with the
fastest leukemia development after transplantation. The CSF2RB- IL1RL1- KITpopulation had the lowest BrdU incorporation rate, correlating with the longer latency
required for leukemia development in mice transplanted with this sub-population (Figure
3.11a).
Most frontline chemotherapies target proliferating cells. Therefore, one would
predict that the most highly proliferative LSC sub-populations would be the most
sensitive to chemotherapeutic drugs. To test this, we cultured each LSC sub-population
on the bone marrow stromal cell line OP-9 and treated with doxorubicin (DOXO). We
found that the two sub-populations with the highest relative proliferation rates, CSF2RBIL1RL1- KIT+ and CSF2RB- IL1RL1+ KIT+ showed a statistically significant decrease in
viability as compared to the untreated cells. Interestingly, the less proliferative
populations showed a trend towards increased relative viability when treated with
DOXO, although this difference was not statistically significant (Figure 3.11b). Together,
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these results imply that Cbfb-MYH11-expressing LSCs can be highly proliferative and
sensitive to chemotherapy in vitro.

73

a

P=0.07

BrdU Incorporation (%)

60

P=0.06

*

*

50

-

-

+
+
CD131-IL1RL1+CKIT+
CSF2RB IL1RL1 KIT

40

-

-

-

-

+

-

CSF2RB IL1RL1 KIT
CD131-IL1RL1-CKIT30

CD131-IL1RL1+CKITCSF2RB IL1RL1 KIT
+

20

CD131+
CSF2RB

10
0
BM

SP

b
3

P=0.07

2.5

2

Relative Viability

+

CD131-IL1RL1-CKIT+
CSF2RB IL1RL1 KIT

1.5

****

*

1

0.5

0
-

-

+

-

+

+

CD131-IL1RL1-CKIT+
CD131-IL1RL1+CKIT+
IL1RL1 KIT
CSF2RB
IL1RL1 KIT CSF2RB

+
CD131-IL1RL1-CKITCSF2RB IL1RL1 KIT CD131-IL1RL1+CKITCSF2RB IL1RL1 KIT

Untreated

DOXO

+
CD131+
CSF2RB+
CSF2RB

74

Figure 3.11. Different proliferation rates and chemotherapy sensitivities in LSC
sub-populations.
(a) Analysis of bromodeoxyuridine (BrdU) incorporation in each LSC sub-population
harvested from bone marrow (BM) and spleen (SP) of mice transplanted with GFPexpressing leukemic cells from 3 independent Cbfb-MYH11+/56M, Mx1-Cre+ mice. Mice
were sacrificed 1 hour after a single BrdU injection.
(b) Bar graph showing the relative viability of each LSC sub-population treated with 4 µM
DOXO for 24 hours on OP-9 cells, as compared to the untreated cells. N≥3. *P <0.05;
****P<0.0001.

75

8.4 LSC markers are dynamic
Our finding that all LSC sub-populations recapitulate the heterogeneity of the
original leukemia sample implies that the sub-populations defined by CSF2RB, IL1RL1,
and KIT are likely not to be organized in a strict hierarchical differentiation scheme.
Rather, the expression of these markers may be dynamic. To test this possibility, we
isolated each LSC sub-population based on their CSF2RB/IL1RL1/KIT expression and
cultured them on OP-9 cells. We then stained cells for marker expression after 6 hours
or 24 hours. We found that regardless of the initial sub-population sorted, the marker
expression changed with time in culture. Interestingly, the CSF2RB- IL1RL1- KIT- subpopulation showed the most stable marker profile in this time frame (Figure 3.12a). To
exclude the possibility that the re-establishment of the marker profile was due to
differences in survival, we compared the viability of each sorted sub-population at 0 hour
and 24 hours. We found that there were no significant differences in viability among the
LSC sub-populations after being cultured for 24 hours, indicating that each subpopulation has similar rates of survival (Figure 3.12b). This finding is consistent with
other recent studies showing the plasticity of marker expression in LSCs and the cancer
stem cells from solid tumors (Gunjal, Pedziwiatr et al. 2015, Lang, Wojcik et al. 2017).
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Figure 3.12. The expression of IL1RL1 and KIT is dynamic.
(a) Bar graph showing the expression of IL1RL1, KIT, and CSF2RB in leukemia cells
from three independent Cbfb-MYH11+/56M, Mx1-Cre+ mice sorted for the indicated subpopulations, after co-culture with OP-9 cells for the indicated time. N=3.
(b) Bar graph showing relative viability of each sorted population after culture on OP-9
cells for 24 hours compared to time zero (0 hour). N=3.
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8.5 IL1RL1 signaling promotes leukemia cell survival
The findings described above imply that the IL1RL1 and KIT cell surface
expression does not identify populations arranged in a hierarchical differentiation
scheme. However, their expression does define populations with distinct growth
characteristics, implying that signaling through these receptors may regulate LSC
activity. KIT is a well-established regulator of leukemia cell survival and activating
mutations in KIT cooperate with Cbfb-MYH11 during leukemia development (Zhao,
Melenhorst et al. 2012). However, whether IL1RL1 similarly regulates AML cells is not
known. To test this hypothesis, we treated mouse leukemia cells with the IL1RL1 ligand,
IL-33, and performed serial replating experiments. Equal numbers of leukemia cells were
plated in methylcellulose in the presence or absence of IL-33. After 14 days of culture,
colonies were counted, and equal numbers were serially replated in methylcellulose
without further addition of IL-33. At both the 1st and 2nd plating, we found that IL-33 led
to a significantly increased number of colonies (Figure 3.13a). To confirm that the effect
of IL-33 is mediated by IL1RL1, we treated cells with IL-33 and a blocking antibody
against IL1RL1. We found that the enhanced colony-forming ability induced by IL-33 is
blocked by the anti-IL1R1L antibody (Figure 3.13b). These results indicate that IL33/IL1RL1 signaling promotes colony-forming ability in Cbfb-MYH11 expressing
leukemia cells. To test if the increase in colony number is related to increased
proliferation, we measured BrdU incorporation and cell cycle status on leukemia cells
treated with IL-33. We found that IL-33 significantly decreased BrdU incorporation, as
well as the percentage of cells in S phase (Figure 3.13c,d), indicating that IL-33 does
not induce proliferation in Cbfb-MYH11+ leukemia cells. To test if increased cell survival
could mediate IL-33’s effect on colony-forming ability, we performed quantitative
reverse-transcription PCR (qRT-PCR) for genes known to be induced by IL-33 in normal
myeloid cells: Bcl-xl, Bcl-2, TRAF-1, TRAF-2, and Mcl-1 (Medearis, Han et al. 2011,
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Portt, Norman et al. 2011). After 6 hours of stimulation with IL-33, we observed
significantly increased expression of Bcl-xl, TRAF-1, TRAF-2, and Mcl-1, but not Bcl-2 in
leukemia cells (Figure 3.13f). By western blot, we found that the protein levels of Bcl-xl,
TRAF-1, and Mcl-1 were less dramatically, but statistically significantly increased in IL33-treated cells, as compared to untreated cells (Figure 3.13g). To test if IL-33
treatment protects cells from apoptosis, we stained leukemia cells with Annexin V. We
found that IL-33-treated cells had statistically significant lower Annexin V staining, and
increased viability, as compared to the untreated cells, and the anti-apoptotic effect of IL33 was blocked by the addition of anti-IL1RL1 antibody (Figure 3.13h). The decreased
proliferation and apoptosis caused by IL-33 raises the possibility that signaling through
IL1RL1 may be involved in chemoresistance. To test this possibility, we examined if
there is a difference in the response between IL1RL1+ and IL1RL1- leukemia cells to
DOXO in vivo. Leukemic Cbfb+/56M, Mx1-Cre+, GFP+ mice were intraperitoneally injected
with DOXO and leukemia cells from spleen and bone marrow were isolated 48 hours
later. We found that the viability of IL1RL1+ cells is significantly higher than IL1RL1- cells
from both spleen and bone marrow, indicating that IL1RL1+ cells are less sensitive to
killing by DOXO as compared to IL1RL1- cells in vivo (Figure 3.14a,b). This result is in
contrast to our in vitro assay, where CSF2RB- IL1RL1+ KIT+ is more sensitive to DOXO
treatment while CSF2RB- IL1RL1+ KIT- population is less sensitive in the presence of
DOXO. Thus, to test whether KIT signaling influences the role of IL1RL1 in cell survival,
we treated leukemic cells from 3 independent Cbfb+/56M; Mx1-Cre+ mice with IL-33, stem
cell factor (SCF, the ligand for KIT) or the combination of IL-33 and SCF in culture for 24
hours and measured apoptosis and cell cycle status. We found that treatment with SCF
or IL-33 caused a significant decrease in apoptosis, as compared to the untreated cells.
The combination of IL-33 and SCF together showed a trend towards decreased
apoptosis, although this difference was not statistically significant as compared to
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treatment with either cytokine alone (Figure 3.15a). Treatment with SCF caused a trend
towards an increase in cells in S phase, although this was not statistically significant.
Interestingly, the combination of SCF and IL-33 did not show a decrease in S phase as
observed with IL-33 alone (Figure 3.15b), which may explain the different sensitivities of
the CSF2RB- IL1RL1+ KIT- and CSF2RB- IL1RL1+ KIT+ populations to DOXO. This is
consistent with previous work showing that KIT and IL1RL1 cooperate to induce
proliferation in mast cells (Drube, Heink et al. 2010). These findings indicate that the
IL1RL1/IL-33 signaling axis promotes leukemia cell colony-forming ability and resistance
to DOXO, perhaps through the upregulation of pro-survival genes and a consequent
block in apoptosis
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Figure 3.13. IL-33 promotes colony formation and survival of primary mouse CbfbMYH11+ leukemia cells.

(a) Bar graph showing the relative number of colonies observed from equal numbers of
Cbfb-MYH11+/56M, Mx1-Cre+ leukemia cells cultured in the presence or absence of IL-33
(100 ng/mL) in methylcellulose. Colonies were scored on day 14 (1st round), and then
equal numbers of cells replated in methylcellulose, without additional IL-33 (2nd round).

(b) Bar graph showing the relative number of colonies observed from equal numbers of
+/56M

+

Cbfb-MYH11
, Mx1-Cre leukemia cells cultured in the presence of IL-33 (100 ng/mL)
or in combination with an anti-IL1RL1 antibody (1µg/mL) in methylcellulose. Colonies
were scored on day 14.

(c) Bar graph showing the relative BrdU incorporation in leukemia cells from CbfbMYH11+/56M, Mx1-Cre+ mice after culture for 24 and 48 hours in the presence or absence
of IL-33 (100 ng/mL) compared to the untreated. Cells were pulse labeled with BrdU for
1 hour.

(d) Bar graph showing the relative percentage of leukemia cells from Cbfb-MYH11+/56M,
Mx1-Cre+ mice in the indicated phase of the cell cycle after culture for 24 hours in the
presence or absence of IL-33 (100 ng/mL).

(e) Bar graph showing the fold changes in mRNA expression of Bcl-xl, Bcl-2, TRAF-1,
TRAF-2, and Mcl-1 in leukemia cells from Cbfb-MYH11+/56M, Mx1-Cre+ mice cultured for
6 hours in the presence or absence of IL-33 (100ng/mL). Relative expression levels
were normalized to that of Actb.

(f) Bar graph of relative protein levels in leukemia cells from four independent CbfbMYH11+/56M, Mx1-Cre+ mice cultured in the presence or absence of IL-33 (100ng/mL).
The membrane was cut into individual blots and incubated with indicated primary
antibodies in separate dishes. After detection of Mcl-1, the blot was stripped and probed
sequentially with antibody to GAPDH.
(g-h) Bar graph showing the relative Annexin V staining and viability in leukemia cells
from Cbfb-MYH11+/56M, Mx1-Cre+ mice after culture for 24 hours in the presence of IL-33
(100ng/mL) or combined with anti-IL1RL1 antibody (1 µg/mL) compared to the untreated
cells. N≥3. *P <0.05; **P <0.01.
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Figure 3.14. IL1RL1+ cells are less sensitive to killing by DOXO.
(a-b) Bar graphs showing the percentage of live cells from spleen and bone marrow
within IL1RL1+ and IL1RL1- populations 48 hours after DOXO administration. N≥3. *P
<0.05.
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Figure 3.15. KIT cooperates with IL1RL1 in inhibiting apoptosis and inducing
proliferation.
(a) Bar graph showing the relative Annexin V staining in leukemia cells from CbfbMYH11+/56M, Mx1-Cre+ mice after culture for 24 hours in the presence of IL-33 (100
ng/mL), SCF (100 ng/mL) or in combination, compared to the untreated cells.
(b) Bar graph showing the relative percentage of leukemia cells from Cbfb-MYH11+/56M,
Mx1-Cre+ mice in the indicated phase of the cell cycle after culture for 24 hours in the
presence of IL-33 (100 ng/mL), SCF (100 ng/mL) or in combination, compared to the
untreated cells. N=3. *P<0.05.
.
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9

Discussion
Previously, we showed that expression of the leukemogenic fusion gene Cbfb-

MYH11 induces changes in gene expression and causes aberrant myeloid differentiation
(Hyde, Kamikubo et al. 2010). Among the most differentially expressed genes are the
cytokine receptors CSF2RB and IL1RL1. We also found that expression of CSF2RB is
associated with decreased LSC activity, implying that CSF2RB signaling is likely not a
major regulator of Cbfb-MYH11+ LSCs. However, the role of IL1RL1 was not known. In
more recent work, IL1RL1 has been shown to be important in other myeloid
malignancies, including CML and myeloproliferative neoplasms (MPN) (Levescot,
Flamant et al. 2014, Mager, Riether et al. 2015). Thus, in this report we examined the
expression of IL1RL1 in the LSC-enriched CSF2RB- population, and the effect of the
IL1RL1 ligand, IL-33, on Cbfb-MYH11 expressing leukemia cells.
By performing LDA in congenic recipient mice, we found that multiple subpopulations in the CSF2RB- fraction had relatively high rates of proliferation and
considerable LSC activity. This is in contrast to most common models of LSCs which
posit that LSCs are mostly quiescent and restricted to a single HSC-like population
(Ishikawa, Yoshida et al. 2007, Gentles, Plevritis et al. 2010, Kreso and Dick 2014,
Thomas and Majeti 2017). However, these models are primarily based on observations
using human patient cells grown in vitro or in immunocompromised mouse models. It is
possible that these experimental conditions only allow for the growth of a limited subset
of LSCs, leading to an underestimation of the full spectrum of cells with LSC activity. In
fact, we found that CSF2RB- IL1RL1+ cells showed significantly impaired colony-forming
ability when grown in vitro, despite their robust ability to cause leukemia when
transplanted into recipient mice. The observed discrepancy between in vitro and in vivo
experiments indicates that in vitro activities of leukemia cells may not reliably predict
their in vivo phenotypes. This implies that cytokines and/or growth factors in the
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microenvironment are likely to play a critical role in regulating the leukemia stem cell
activity. Studies using other mouse models have similarly shown that LSCs can be
highly proliferative and are not restricted to an HSC-like population (Somervaille and
Cleary 2006, Bereshchenko, Mancini et al. 2009, Shih, Jiang et al. 2015). Collectively,
these studies imply that LSCs are more diverse and less quiescent than what has been
indicated by in vitro or xenograft assays. Furthermore, our finding that LSC activity
correlates with proliferation in Cbfb-MYH11+ leukemia may also partly explain the
favorable response of inv(16) AML patient to traditional chemotherapy.
We also found that KIT and IL1RL1 did not identify a single LSC population that
was clearly at the apex of a hierarchical differentiation scheme. Rather, we found that,
aside from the CSF2RB- IL1RL1- KIT- population, which had very little LSC activity, each
of the sorted sub-populations able to recapitulate the immunophenotypic diversity of the
original leukemia sample in spite of their different growth characteristics and latencies in
vivo. We can only speculate at the reasons why different populations have different
growth kinetics. Presumably, it is related to signaling through the specific cytokine
receptors expressed, which may in turn affect gene expression. We found that there is
no significant difference in the expression of Cbfb-MYH11 among each LSC subpopulation, indicating that the differences in behavior among the different LSC subpopulations are not due to differences in expression of the fusion protein. However, it is
possible that the activity of Cbfb-MYH11 influenced by cell surface signaling, which may
contribute to the growth kinetics of the different sub-populations.
We found that the immunophenotype of the sorted sub-populations was altered
in as short as 6 hours in culture. This indicates that the expression of KIT and IL1RL1 is
highly dynamic and may not be restricted to a specific stage of differentiation. Currently,
we cannot rule out the possibility that this plasticity is due to rapid de-differentiation of
the different sub-populations which allows them to give rise to cells with more stem-cell
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like characteristics. However, our findings are similar to recent work in B-cell precursor
acute lymphoblastic leukemia (BCP-ALL) demonstrating that expression of the human
HSPCs markers CD34 and CD38 is highly plastic at the single cell level and recent work
in AML showing a non-hierarchical relationship between CD34+ and CD34- LSCs (Quek,
Otto et al. 2016, Lang, Wojcik et al. 2017).
Currently, we can only speculate as to the molecular mechanisms underlying the
observed plasticity. It is possible that the expression of these cell surface marker
changes in response to different environmental stimuli. In fact, the dynamic expression
of KIT and IL1RL1 in leukemia cells suggests that these receptors may be regulating cell
processes other than differentiation. KIT is known to be important specifically in inv(16)
AML. Activating mutations in KIT are found frequently in inv(16) patient samples and are
known to cooperate with Cbfb-MYH11 during leukemia development (Zhao, Melenhorst
et al. 2012, Cancer Genome Atlas Research, Ley et al. 2013, Paschka, Du et al. 2013,
Ayatollahi, Shajiei et al. 2016, Duployez, Marceau-Renaut et al. 2016). Here we show
that signaling through the IL1RL1 receptor also plays a role in leukemia cell survival. We
found that treatment of Cbfb-MYH11+ leukemia cells with exogenous IL-33, the only
known IL1RL1 ligand, reduced apoptosis and proliferation, and increased serial replating
ability. This implies that IL1RL1 is important for LSC survival and self-renewal, which
may partially explain the discrepancy between in vitro and in vivo assays for LSCs.
These findings are similar to what has been shown in CML where IL-33 promotes LSC
survival (Levescot, Flamant et al. 2014). Importantly, the anti-apoptotic effect by IL-33 is
subtle compared to the effect on colony-forming ability, implying that IL-33 is likely to
affect other pathways in addition to apoptosis. Finally, we found that IL1RL1+ CbfbMYH11+ cells are less sensitive to treatment with doxorubicin, implying that IL-33/IL1RL1
signaling may promote cell survival in response to chemotherapy.
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Taken together, our studies demonstrate that IL1RL1 is a potentially important
regulator of CBFB-MYH11+ LSCs. Further, our results contribute to a growing body of
evidence that LSCs may be more diverse than previously thought.
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CHAPTER IV
Cbfb-MYH11 is required for the survival of inv(16) leukemia
cells
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10 Abstract
Inversion of chromosome 16 [inv(16)] is found in 10-15% of human AML cases. Inv(16)
AML generates a fusion gene called CBFB-MYH11, which encodes the fusion protein
CBFβ-SMMHC (core binding factorβ-smooth muscle myosin heavy chain). CBFBMYH11 expression is known to be the initiating event in leukemogenesis. However, to
develop frank leukemia, cooperating mutations are required, the most common of which
confer a proliferative advantage. CBFB-MYH11 is only expressed in leukemic blasts but
not in normal hematopoietic cells. Thus, targeting CBFB-MYH11 may be a promising
strategy to treat inv(16) AML in the near future. However, the biological role of CBFBMYH11 in the leukemia maintenance is currently poorly understood. Using a new knockin mouse model which allows for deletion of Cbfb-MYH11 by Cre recombinase (Cre), we
found that the loss of Cbfb-MYH11 caused increased apoptosis and decreased colonyforming ability as compared to control. To confirm our observation using Cbfb+/flMYH11
leukemia cells, we transduced leukemia cells from Cbfb-MYH11+/56M, Mx1-Cre+ mice with
a doxycycline (DOX) inducible-shRNA against MYH11 and examined the effect of CbfbMYH11 knockdown both in vitro and in vivo. We found that knockdown of Cbfb-MYH11
decreased leukemia burden, increased differentiation and prolonged survival in vivo.
Overall, our data indicates that Cbfb-MYH11 is an important regulator for the
maintenance of inv(16) AML, and is thus a potential therapeutic target for treating AML.

11 Introduction
Inversion 16 [inv(16)] AML is one subtype of AML, occurring in 10-15% of all
AML cases and having a 5-year survival approximately 50% to 60% (Ravandi, Burnett et
al. 2007, Pulsoni, Iacobelli et al. 2008). Inv(16) AML generates a fusion between the
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CBFB gene encoding CBFβ (core binding factor β) and the MYH11 gene encoding
smooth-muscle myosin heavy chain (SMMHC). The expression of CBFB-MYH11 is
known to be the initiating event in inv(16) AML, leading to the production of abnormal
myeloid cells which can transform to frank leukemia upon the acquisition of cooperating
mutations (Castilla, Garrett et al. 1999). To date, the role of CBFB-MYH11 during
leukemic maintenance is not well understood.
Because the CBFB-MYH11 fusion gene is only expressed in leukemia cells,
developing inhibitors for the fusion protein represents a promising therapeutic strategy
for treating AML. Two inhibitors targeting CBFβ-SMMHC have been developed, Ro53335 and AI-10-49, both of which induce apoptosis and decrease leukemic burden in
mice (Cunningham, Finckbeiner et al. 2012, Illendula, Pulikkan et al. 2015). However,
mice treated with those inhibitors eventually died from leukemia, which may be due to
ineffective inhibition of CBFβ-SMMHC activity. It is also possible that frank leukemia
cells can still survive with the loss of CBFB-MYH11 activity. To test the second
possibility, Mandoli et al used an shRNA-mediated knockdown of CBFB-MYH11 in
human inv(16) AML cell line, ME-1. They found that CBFB-MYH11 knockdown only
modestly increases differentiation without affecting cell survival or proliferation (Mandoli,
Singh et al. 2014). However, ME-1 cells are immortalized and contain additional
mutations, raising the possibility that they are not a suitable model to study the role of
CBFB-MYH11.
To test whether CBFB-MYH11 is required to maintain leukemia, we generated a
new knock-in mouse model, where the Cbfb-MYH11 allele is flanked by loxP sites
(CbfbflMYH11). This Cbfb-flMYH11 allele can be deleted by Cre recombinase (Cre) after
leukemic transformation. We found that leukemia cells from chimeric mice with this allele
show a similar histological appearance and immunophenotype as leukemia cells derived
from previous Cbfb-MYH11 knock-in models. In addition, we found that deletion of the
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Cbfb-MYH11 allele increased Annexin V staining and decreased colony-forming ability of
leukemia cells as compared to control in vitro. To confirm these results, we developed a
second mouse model using a doxycycline (DOX) inducible shRNA against MYH11
(shMYH11). We observed that DOX treatment caused a moderate knockdown of CbfbMYH11 compared to the vehicle. To test the phenotype with knockdown of Cbfb-MYH11
in vivo, recipient mice were transplanted with shMYH11-transduced leukemia cells and
treated with DOX after developing leukemia. We found that there was a significant
decrease in leukemic burden, increased differentiation and a prolonged survival in DOXtreated mice as compared to vehicle-treated mice. Interestingly, we observed that
shMYH11-transduced leukemia cells re-emerged in some mice treated continuously with
DOX, implying that Cbfb-MYH11 may not be strictly required by leukemia cells to
survive.
Collectively, our study implies that Cbfb-MYH11 is important for the maintenance
of leukemia cells both in vitro and in vivo. Therefore, inhibition of CBFB-MYH11 may be
of therapeutic potential for treating inv(16) AML. However, some leukemia cells lacking
Cbfb-MYH11 may still survive, implying that Cbfb-MYH11 inhibition alone may not be
able to cure inv(16) AML.

12 Results
12.1

Generation of CbfbflMYH11 leukemia cells
To test the requirement of CBFB-MYH11 after leukemic transformation, Hyde et

al developed a new knock-in mouse with the MYH11 allele flanked by loxP sites
(CbfbflMYH11). Thus, this construct allows for the deletion of Cbfb-MYH11 gene by Cre
recombinase (Figure 4.1a) (Hyde, Liu, et al., unpublished data). In order to identify
clones that could be used to generate chimeric mice, both southern blot and western blot
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analysis were performed on individual embryonic stem (ES) clones. We identified 3
clones that gave the expected fragments of DNA after digestion with the NcoI restriction
enzyme. Furthermore, Cbfβ-SMMHC protein is highly expressed from cell lysates from
ES cells with the Cbfb-flMYH11 allele (Figure 4.1b,c) (Hyde, Liu, et al., unpublished
data). To test if the flMYH11 allele can be deleted by Cre, CbfbflMYH11 chimeras were
mated with transgenic mice expressing Cre from the β–Actin promoter (ActB Cre). We
found that the embryos with Cbfb+/flMYH11 had lethal central nervous system hemorrhages
at day 12.5, which is the same phenotype as mouse embryos heterozygous for the nonfloxed Cbfb-MYH11 allele (Castilla, Wijmenga et al. 1996). In contrast, the embryos from
Cbfb+/flMYH11ActB Cre+ did not exhibit hemorrhages. To verify excision of the CbfbflMYH11 allele, DNA was isolated from the embryonic tissues. We found that the CbfbMYH11 gene was efficiently deleted from the embryo expressing Cbfb+/flMYH11, ActB Cre+
(Figure 4.1d,e) (Hyde, Liu, et al., unpublished data). We treated three Cbfb+/flMYH11
chimeric mice with the mutagen N-ethyl-N-nitrosourea (ENU) to introduce cooperating
mutations and monitored them for leukemia development. This result indicates that we
were able to generate leukemic chimeric mice with a single Cbfb-flMYH11 allele, which
further implies that we can utilize this Cre-lox system to study the role of Cbfb-MYH11
during leukemia maintenance in vitro and in vivo.
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Figure 4.1. Generation of knock-in mouse embryos with a single Cbfb-MYH11
allele.
(a) Schematic representation of the ES-cell targeting strategy. The probe (0.2C) and
restriction enzyme sites (NcoI) used for screening are indicated. The black arrows
represent primers for the excised allele, and the purple arrows represent primers for the
unexcised allele.
(b) Southern blot analysis using the 0.2C probe of NcoI-digested DNA from untargeted
and correctly targeted ES cells clones.
(c) Western blot analysis for CBFβ-SMMHC using cell lysates from targeted and
parental ES cells using an antibody against CBFβ.
(d) Cbfb-flMYH11 chimeras were mated with transgenic mice expressing Cre
recombinase (Cre) from the β–Actin promoter (ActB Cre). Embryos were harvested at
embryonic day 12.5, photographed, and DNA harvested for genotyping and excision of
the Cbfb-flMYH11 allele (left). PCR analysis of DNA extracted from embryos for the
excised and unexcised Cbfb-flMYH11 allele (right)
(e) Experimental design to test the role of Cbfb-MYH11 in leukemia maintenance. ES,
embryonic stem cells; ENU, N-ethyl-N-nitrosourea; TK, thymidine kinase.
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12.2

Characterization of CbfbflMYH11 leukemia cells
To accelerate leukemia development, the mutagen N-ethyl-N-nitrosourea (ENU)

was used to treat three independent CbfbflMYH11 chimeric mice. At the first sign of
sickness, bone marrow and spleen leukemic cells were harvested from leukemic
chimeric mice. To test whether our chimeric mice developed transplantable leukemia, we
injected leukemic spleen cells from chimeric mice into sub-lethally irradiated mice. We
found that the leukemia cells generated from the three chimeric mice caused leukemia in
recipient mice, with similar latency as previously described for the conditional CbfbMYH11 knock-in mouse model (Figure 4.2a) (Kuo, Landrette et al. 2006). To examine
the immunophenotype of leukemic cells developed from the chimeric mice, we stained
leukemia cells from the peripheral blood for lymphoid lineage markers (CD3 and B220),
myeloid lineage markers (GR-1, and MAC-1) and markers abnormally upregulated in
inv(16) AML (KIT and CSF2RB) by flow cytometry (Kuo, Landrette et al. 2006, Hyde,
Kamikubo et al. 2010). Peripheral blood samples from wild-type mice were used as a
control. We found that the population of lymphoid and mature myeloid cells from mice
transplanted with CbfbflMYH11 leukemia cells was decreased as compared to samples
from wild-type mice. In addition, we observed an increase in the cell population
expressing both CSF2RB and KIT in CbfbflMYH11 leukemia cells-transplanted mice
compared to the healthy wild-type mice (Figure 4.2b,c). Histological examination of
tissues from CbfbflMYH11 leukemic mice showed the accumulation of myeloid blasts in the
peripheral blood, spleen and liver, indicating a similar histological appearance to
leukemia cells generated from previous Cbfb-MYH11 knock-in models (Figure 4.2d).
Overall, our data indicate that the primary leukemia cells generated from chimeric
CbfbflMYH11 mice are a true transplantable leukemia with a similar phenotype as previous
Cbfb-MYH11 knock-in models, indicating that CbfbflMYH11 mice are a suitable model of
inv(16) AML (Kuo, Landrette et al. 2006, Hyde, Kamikubo et al. 2010).
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Figure 4.2. CbfbflMYH11 leukemic mice show similar phenotype to the previous CbfbMYH11 mouse model.
(a) Kaplan-Meier Survival curves of mice transplanted with CbfbflMYH11 leukemia cells
from three independent clones.
(b) Representative FACS analysis with the indicated antibodies of peripheral blood from
a healthy mouse and a leukemic recipient mouse transplanted with CbfbflMYH11 cells.
(c) Bar chart showing the percentages of spleen cells expressing CD3, B220, MAC-1,
GR-1, CSF2RB, and KIT from CbfbflMYH11 leukemic mice.
(d) Wright-Giemsa staining of peripheral blood cells, and hematoxylin & eosin stained
sections of spleen and liver from a representative leukemic CbfbflMYH11 recipient mouse.
N=3. *P<0.05; **P<0.01; ***P<0.001.
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12.3

Cbfb-MYH11 is required for the growth of leukemia cells in vitro
To examine the role of Cbfb-MYH11 in transformed leukemia cells, we

transduced Cbfb+/flMYH11 leukemia cells from three independent chimeric CbfbflMYH11 mice
with lentivirus expressing either Cre and GFP or control viruses expressing only GFP.
We sorted cells for GFP expression 48 hours after transduction. To test the excision
efficiency of Cbfb-MYH11, real-time PCR was performed. We found that mRNA and
protein levels of Cbfb-MYH11 were significantly decreased compared to cells transduced
with the control lentivirus (Figure 4.3a,b). To test the effect of the deletion of CbfbMYH11 on apoptosis, we used Annexin V staining 48 hours after transduction. We found
that Cre-infected leukemia cells showed a statistically significant increase in Annexin V
staining compared to cells infected by control virus, indicating that the deletion of CbfbMYH11 causes increased apoptosis. To test if deletion of Cbfb-MYH11 induced myeloid
differentiation, we stained Cre- and control-infected CbfbflMYH11 leukemia cells for two
myeloid differentiation markers, Gr-1 and Mac-1. We found that the expression of Mac-1
was significantly increased in Cre-infected cells as compared to the control (Figure
4.3d). To examine the effect of the deletion of Cbfb-MYH11 on LSC activity in vitro, we
performed serial replating experiments. We plated equal numbers of leukemia cells
transduced with Cre or control lentivirus in methylcellulose and counted the colonies
after 14 days of culture. We found that Cre-infected cells produced significantly fewer
colonies at both the 1st and 2nd plating (Figure 4.3e). Our results indicate that CbfbMYH11 is required for leukemia maintenance in vitro.
To determine if the colonies that did grow from Cre-infected cells had
successfully deleted Cbfb-MYH11, we picked individual colonies and performed realtime PCR. We found that the frequency of colonies with deleted Cbfb-MYH11 allele
ranged from 5% to 20% (Figure 4.4a,b). The data indicate that leukemia cells may not
strictly require Cbfb-MYH11 to survive in long-term culture. Our observations also imply
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that targeting Cbfb-MYH11 alone may not be effective as a means to eliminate all
leukemia cells.
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Figure 4.3. Deletion of Cbfb-MYH11 decreased leukemia cell growth in vitro.
(a) Bar graphs showing the PCR analysis for the unexcised and excised Cbfb-flMYH11
alleles.
(b) Western blot analysis of CBFβ-SMMHC in Cbfb+/flMYH11 leukemia cells infected with
Cre and control virus.
(c) Representative histograms (left) and bar graph (right) showing Annexin V+ cells in
Cre- and control- transduced Cbfb+/flMYH11 leukemia cells.
(d) Bar graph showing the relative Mac-1 expression in Cbfb+/flMYH11 leukemia cells
infected with Cre and control virus.
(e) Bar graph showing the relative number of colonies observed from equal numbers
of Cre and control transduced Cbfb+/flMYH11 leukemia cells plated in methylcellulose.
Colonies were scored on day 14. N=3. *P<0.05; ***P<0.001.
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Figure 4.4. Colonies with the deletion of Cbfb-MYH11 can survive in vitro.
(a) Estimated frequency of colonies with the deletion of Cbfb-MYH11 that still

survived in prolonged culture in methylcellulose.
(b) Representative agarose gel image of real-time PCR showing the unexcised and
excised allele from leukemia cells transduced with CRE or CTRL lentivirus and plated for
CFC assay for 14 days in culture.
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12.4

Doxycycline-inducible shRNA causes efficient knockdown of Cbfb-MYH11

in vitro
To test if Cbfb-MYH11 is required for the survival of leukemia cells in vivo, we
used a DOX-inducible Cbfb–MYH11 shRNA vector (shMYH11) coexpressing GFP from
an internal ribosome entry site (IRES), as described previously (Mandoli, Singh et al.
2014). We transduced leukemia cells from three independent Cbfb-MYH11 knock-in
mice with shMYH11 and sorted cells for GFP expression 48 hours after lentiviral
transduction. To test the feasibility of this approach in vitro, the sorted GFP+ cells were
incubated with DOX for 24 hours in culture. To measure the knockdown efficiency, the
mRNA and protein expression of Cbfb-MYH11 were examined by qRT-PCR and western
blot. We found that Cbfb-MYH11 mRNA and protein were significantly lower in cells
treated with DOX as compared to untreated cells (Figure 4.5a,b). To test the effect of
Cbfb-MYH11 knockdown on apoptosis, we used Annexin V staining. We found that
leukemia cells incubated with DOX showed significantly higher Annexin V staining as
compared to the untreated cells (Figure 4.5c). To determine the effect of Cbfb-MYH11
knockdown on LSC activity in vitro, we performed colony formation assays. Sorted CbfbMYH11+ leukemia cells transduced shMYH11 were treated with or without DOX in
culture. Cells were plated in methylcellulose 24 hours later. After 14 days of culture,
colonies were counted. We found that leukemia cells treated with DOX produced
significantly fewer colonies compared to the control group (Figure 4.5d). These results
indicate that the DOX- inducible shMYH11 lentiviral system causes efficient knockdown
of Cbfb-MYH11. More importantly, the effect by Cbfb-MYH11 knockdown confirms the
phenotype we observed previously using with the CbfbflMYH11 knock-in mouse model.
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Figure 4.5. Cbfb-MYH11 knockdown in vitro by shMYH11
(a) Bar graph showing the fold change in mRNA expression of Cbfb-MYH11 alleles in
shMYH11-transduced leukemia cells from Cbfb-MYH11+/56M, Mx1-Cre+ mice cultured in
the presence or absence of DOX for 24 hours in culture.
(b) Western blot analysis of CBFβ-SMMHC in shMYH11-transduced leukemia cells
from Cbfb-MYH11+/56M, Mx1-Cre+ mice cultured in the presence or absence of DOX
for 24 hours in culture.
(c) Bar graph showing the percentage of Annexin V+ cells in shMYH11-transduced
leukemia cells from Cbfb-MYH11+/56M, Mx1-Cre+ mice cultured in the presence or
absence of DOX for 24 hours in culture.
(d) Bar graph showing the relative number of colonies observed from equal numbers
of shMYH11-transduced leukemia cells from Cbfb-MYH11+/56M, Mx1-Cre+ mice
cultured in the presence or absence of DOX in methylcellulose. Colonies were scored
on day 14. UT,untreated. N=3. *P<0.05; ***P<0.001.
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12.5

Cbfb-MYH11 is required for leukemia maintenance in vivo
To test if Cbfb-MYH11 is required in vivo, shMYH11-transduced leukemia cells

were sorted for GFP expression and transplanted into sub-lethally irradiated mice.
Approximately 2 weeks later, peripheral blood was analyzed to confirm leukemia
engraftment based on GFP expression, and the mice were treated with DOX in their
drinking water. PB, BM, and spleen were harvested after mice were sacrificed after4, 7
and 21 days of treatment. Knockdown of Cbfb-MYH11 was confirmed by qRT-PCR
analysis of mRNA level on days 4 and 7 post-treatment. We found that DOX treatment
led to a substantial knockdown of Cbfb-MYH11 in leukemia cells at the two time points
as compared to the vehicle treated mice, although the differences were not statistically
significant (Figure 4.6a). In addition, on both day 7 and day 21, DOX treatment led to a
significant reduction in the number of leukemia cells determined by GFP expression in
the PB, spleen and BM, as compared to the vehicle group (Figure 4.6b). By staining
cells with 4',6-diamidino-2-phenylindole (DAPI), we found that Cbfb-MYH11 knockdown
led to a significant decrease in leukemia cell viability in the PB, spleen, and BM
compared to untreated group (Figure 4.6c). To test whether Cbfb-MYH11 knockdown
caused decreased viability via apoptosis, we stained cells from the PB, spleen and BM
with Annexin V. We found that treatment with DOX increased Annexin V staining on both
day 7 and day 21 compared to the vehicle-treated mice (Figure 4.6a). To determine if
Cbfb-MYH11 knockdown is associated with increased differentiation, we stained cells
from PB, spleen and BM for Mac-1 and Gr-1, markers of mature myeloid cells. There
was a statistically significant increase of both Mac-1 and Gr-1 expression within GFP+
population in DOX-treated mice, as compared to untreated mice (Figure 4.6e,f).
We also observed that Cbfb-MYH11 knockdown led to a reduction in spleen size and
in spleen weight on day 21 as compared to the vehicle (Figure 4.6g).
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We next sought to determine whether Cbfb-MYH11 knockdown leads to impaired
progression of leukemia in vivo. After sub-lethally irradiated mice were transplanted with
shMYH11-infected leukemia cells, we treated them with DOX or vehicle and examined
GFP+ leukemia cells in the PB weekly. We found that GFP+ cells in PB from untreated
mice increased in a timely manner, with all vehicle treated mice developing lethal
disease by day 21. In the contrast, GFP expression in the PB from DOX-treated mice
decreased after the start of treatment and was reduced to nearly undetectable levels at
day 21 (Figure 4.7a). Furthermore, Cbfb-MYH11 knockdown led to an increased
disease latency compared with control mice (Figure 4.7b). Interestingly, we observed
that two of the DOX-treated mice regained GFP+ cells in their PB at day 28, though the
percentage of GFP+ cells in the PB remained low. We further examined the percentage
of GFP+ cells in the BM and spleen from recipient mice by flow cytometry after the mice
were sacrificed. We found that vehicle mice had a significantly higher percentage of cells
expressing GFP compared to cells from DOX-treated mice, indicating that DOX-treated
mice developed leukemia caused by the non-GFP population (Figure 4.8a). To gain a
better understanding of how GFP- cells appeared in DOX-treated mice, we stained cells
from BM for KIT and CSF2RB, two markers abnormally upregulated in inv(16) AML after
mice were sacrificed (Hyde, Kamikubo et al. 2010). Interesting, we observed that the
expression of CSF2RB and KIT in the GFP+ population was similar to that of GFPpopulation in DOX-treated samples. In contrast, the GFP- population has decreased
expression of KIT or CSF2RB as compared to GFP+ population in vehicle-treated
samples (Figure 4.8b). By measuring the mRNA expression level of Cbfb-MYH11 from
BM and spleen, we found that there was no significant change in the expression level of
Cbfb-MYH11 between vehicle- or DOX-treated samples (Figure 4.8c). Our data indicate
that the DOX-treated mice eventually developed leukemia consisting of both GFP+ and
GFP- populations with similar level of Cbfb-MYH11 expression. It is possible that the
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non-GFP cells arose from GFP+ cells that silenced the shMYH11/GFP construct or from
mis-sorted, non-transduced leukemia cells during flow cytometry. To test this possibility,
we examined the presence of GFP from the shMYH11-expressing lentiviral plasmid, as
well as a non-coding region of the viral vector after isolating the genomic DNA. We
observed that the amplification of GFP is much lower in cells from DOX-treated samples
than vehicle. The same trend was found when we compared the amplification of the noncoding region from DOX-treated samples to the vehicle (Figure 4.8d). Our findings
indicate that non-GFP leukemic cells that emerged after prolonged DOX treatment do
not appear to derive from shMYH11-transduced leukemia cells that silenced the shRNA
expression after DOX treatment. Rather, our data indicate that rare GFP- cells were missorted and became the dominant population when shMYH11-transduced leukemia cells
died due to knockdown of Cbfb-MYH11 expression.
Taken together, our data indicate that Cbfb-MYH11 knockdown decreases
leukemia burden, promotes differentiation and prolongs survival, which further supports
our hypothesis that Cbfb-MYH11 is required for the maintenance of leukemia in vivo.
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Figure 4.6. Cbfb-MYH11 knockdown decreased cell survival in vivo
(a) Bar graphs showing the fold change in mRNA expression of Cbfb-MYH11 alleles in
BM and spleen from mice transplanted with shMYH11-transduced Cbfb-MYH11
expressing leukemia, and treated with vehicle or DOX for 4 or 7 days.
(b-f) Bar graphs showing the percentage of GFP+, Viable, Annexin V+, Mac-1+, and Gr-1+
Cbfb-MYH11+ leukemia from mice transplanted with shMYH11-transduced, and treated
with vehicle or DOX for 7 or 21 days.
(g) Representative images of vehicle or DOX-treated spleens (left) and quantification of
spleen weights (right). N≥3. *P<0.05; **P<0.01; ***P<0.001 ***P<0.0001.
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Figure 4.7. Cbfb-MYH11 knockdown leads to impaired progression of leukemia in
vivo.
(a) Graph showing the percentage of GFP+ cells in the peripheral blood with treatment
with vehicle or DOX in the indicated timepoints
(b) Kaplan-Meier curve of mice transplanted with shMYH11-transduced Cbfb-MYH11
expresssing leukemia, and treated with vehicle or DOX. N≥3.
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Figure 4.8. Non-GFP leukemic cells emerged and caused leukemia in DOX-treated
mice.
(a) Bar graphs showing the percentage of GFP+ leukemia cells in BM and spleen from
vehicle or DOX-treated mice after mice were sacrificed.
(b) Representative FACS plots showing the percentage of CSF2RB and KIT in GFP+
population from BM or spleen after mice were sacrificed.
(c) Bar graphs showing the fold change in mRNA expression of Cbfb-MYH11 in BM and
spleen from vehicle or DOX-treated mice after mice were sacrificed.
(d) Bar graphs showing the fold change in mRNA expression of GFP and a non-coding
region of the viral vector in BM and spleen from vehicle or DOX-treated mice after
mice were sacrificed. N≥3. **P<0.01.
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13 Discussion
Even though patients with inv(16) AML tend to respond well to current therapies,
the 5-year survival rate remains low mainly due to relapse after remission. Therefore,
novel therapies are needed for better outcomes. In inv(16) AML, the fusion gene, CBFBMYH11, is only expressed in leukemia cells but not in healthy cells. Therefore, targeting
CBFB-MYH11 represents a promising therapeutic approach. Different inhibitors targeting
the fusion protein’s activity have been developed and showed promising anti-leukemia
effects in tissue culture and animal models. However, those inhibitors do not completely
eliminate leukemia cells in mice (Cunningham, Finckbeiner et al. 2012, Illendula,
Pulikkan et al. 2015, Illendula, Gilmour et al. 2016). It is possible that those inhibitors do
not effectively inhibit CBFβ-SMMHC activity. In addition, the biology of CBFB-MYH11
after leukemia transformation has been poorly understood. Thus, better understanding of
the role of CBFB-MYH11 during the maintenance of leukemia will help improve the drug
development for treating inv(16) AML.
In this study, we first developed a new knock-in mouse model where the MYH11
tail is flanked by loxP sites, allowing for the conditional deletion of the Cbfb-MYH11 allele
by Cre recombinase. By transducing CbfbflMYH11 leukemia cells with lentivirus expressing
Cre, we were able to efficiently delete Cbfb-MYH11. We found that the loss of CbfbMYH11 in vitro led to decreased viability and increased apoptosis as well as decreased
colony-forming ability. By using a DOX-inducible shRNA targeting MYH11, we found that
knockdown of Cbfb-MYH11 significantly reduced the leukemic burden, induced
differentiation and prolonged survival in vivo. Our results indicate that Cbfb-MYH11 is
required for leukemia maintenance. Previous work using the human inv(16) AML cell
line, ME-1, demonstrated that knockdown of CBFB-MYH11 caused a phenotype that
mimics differentiation, but that knockdown did not cause apoptosis or cell death. One
explanation may be that the immortalized human cell line has acquired unknown genetic
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mutations, which may allow for the survival of ME-1 cells after loss of CBFB-MYH11. In
addition, ME-1 cells are known to lose the inverted copy of chromosome 16 after
prolonged culture (Hyde and Liu, unpublished observations). Loss of the inverted
chromosome 16 is never observed in inv(16) patients, even at relapse (Xiaosu, Leqing et
al. 2019). Therefore, ME-1 cells may not be a good model for studying human disease.
Thus, using a mouse model of human inv(16) AML will be useful to validate the previous
observations that CBFB-MYH11 is an important regulator during maintenance of
leukemia.
To further verify our finding from in vitro study, we transduced leukemia cells
from Cbfb-MYH11 knock-in mice using a DOX-inducible shRNA targeting MYH11
(shMYH11) and transplanted the infected cells into recipient mice. Treating the recipient
mice with DOX after the engraftment of GFP+ leukemia cells led to large-scale cell death
and decreased leukemia burden in our short-term study. However, when the treatment
lasted for more than three weeks, leukemia cells started to reappear, as indicated by the
presence of GFP+ cells in each tissue and DOX-treated mice died of leukemia which had
both GFP+ and GFP- populations. To explain the presence of GFP- cells that caused
leukemia in DOX-treated mice, it is possible that rare non-GFP leukemia cells were
sorted after lentiviral infection and later transplanted into recipient mice. As a result of
DOX treatment and loss of Cbfb-MYH11 in transduced cells, the untransduced
population may have become dominant and eventually caused lethal disease. To solve
this problem in the future, we will need to optimize our sorting strategy to prevent the
contamination of untransduced cells. One strategy would be to perform double sorting
for more purified populations. To explain the re-emergence of GFP+ cells after treating
mice with DOX for longer time, there are several possibilities. Firstly, Cbfb-MYH11
knockdown may allow leukemia cells to gain additional mutations that can compensate
for the loss of Cbfb-MYH11. As a result, those leukemia cells may still grow even with
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continued DOX treatment. It is also possible that leukemia cells under the pressure of
losing Cbfb-MYH11 may re-express Cbfb-MYH11 by acquiring additional mutations. It is
also possible that LSCs in the bone marrow environment are supported by different
types of cytokines or growth factors, which help them to survive with the loss CbfbMYH11 expression.
Our findings are similar to previous work in chronic myeloid leukemia (CML)
driven by the oncogene Bcr-Abl. Hamilton et al demonstrated that the survival of CML
stem cell population does not depend on Bcr-Abl kinase activity, which is the initiating
mutation in this form of CML (Hamilton, Helgason et al. 2012).
Overall, our study provides evidence that Cbfb-MYH11 is required for maintaining
leukemia cells survival in vitro and in vivo. Using the inducible shRNA system against
Cbfb-MYH11 helps us to better understand the biology of CBFB-MYH11, which will
eventually aid effort in drug development.

120

CHAPTER V
Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles
for treatment of acute myeloid leukemia
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14 Abstract
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and
is associated with poor long-term survival often due to relapse. Current treatments for
AML are associated with considerable toxicity and are frequently not effective after
relapse. Thus, it is important to develop novel therapeutic strategies. Short interfering
RNA (siRNA)-based therapeutics targeting key oncogenes have been proposed as
treatments for AML. We recently developed novel siRNA delivery polycations (PCX)
based on AMD3100 (plerixafor), an FDA-approved inhibitor of the chemokine receptor
CXC chemokine receptor 4 (CXCR4). Inhibitors of CXCR4 have been shown to sensitize
leukemia cells to chemotherapy. Therefore, PCX has the potential to target leukemia
cells via two mechanisms: inhibition of CXCR4 and delivery of siRNAs against critical
genes. In this report, we show that PCX exerts a cytotoxic effect on leukemia cells more
effectively than other CXCR4 inhibitors, including AMD3100. In addition, we show that
PCX can deliver siRNAs against the transcription factor RUNX1 to mouse and human
leukemia cells. Overall, our study provides the first evidence that dual-function
PCX/siRNA nanoparticles can simultaneously inhibit CXCR4 and deliver siRNAs
targeting key oncogenes in leukemia cells and that PCX/siRNA has clinical potential for
the treatment of AML.

15 Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized
by the accumulation of immature myeloid cells in the bone marrow. It is the most
common type of acute leukemia in adults, and its incidence increases with age (Dohner,
Weisdorf et al. 2015, Papaemmanuil, Gerstung et al. 2016, Saultz and Garzon 2016,
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Briot, Roger et al. 2018). Current treatments for AML include high-dose chemotherapy
and stem cell transplantation, both of which are associated with significant morbidity and
mortality (De Kouchkovsky and Abdul-Hay 2016, Andresen and Gjertsen 2017, Briot,
Roger et al. 2018). In addition, even with optimal treatment, AML patients frequently
relapse, which in part explains why the prognosis for AML remains poor with the overall
5-year survival rate of only 27% (Andresen and Gjertsen 2017). Thus, there is an urgent
need to develop novel therapeutics to improve treatment outcomes for patients with
AML.
Compared to other cancers, AML has a low mutational burden (Alexandrov, NikZainal et al. 2013, Cancer Genome Atlas Research, Ley et al. 2013). For this reason,
AML cells are likely dependent on a relatively small number of oncoproteins, which are
good candidates for targeted therapies. However, many AML mutations involve
transcription factors, which are difficult to target with traditional small molecules. For
example, efforts to develop inhibitors of RUNX1, one of the most commonly mutated
genes in AML, have shown potential in tissue culture and mouse models, but there have
not yet been any compounds identified suitable for use in humans (Cunningham,
Finckbeiner et al. 2012, Illendula, Pulikkan et al. 2015, Illendula, Gilmour et al. 2016).
Short interfering RNAs (siRNAs) have the potential to overcome these limitations as they
are based on nucleic acid sequence, and not protein structure. Successfully targeted
delivery of siRNAs against specific oncogenes has been reported in a variety of different
types of cancer, including AML (Wilda, Fuchs et al. 2002, Devi 2006, Seton-Rogers
2012, Kaur, Rath et al. 2018). However, the clinical translation of such therapies has
been difficult, mainly due to nuclease degradation during siRNA delivery (Deng, Wang et
al. 2014, Xin, Huang et al. 2017). Thus, strategies for enhancing cellular uptake and
allowing siRNA to specifically reach the target cells are required.
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We have recently developed polymeric CXCR4 antagonists (PCX) which are
capable of inhibiting CXCR4 and carrying siRNA simultaneously (Li, Zhu et al. 2012,
Wang, Li et al. 2015, Xie, Wang et al. 2018). PCX was synthesized from AMD3100
(plerixafor), an FDA-approved CXCR4 inhibitor, and modified with cholesterol for better
systemic delivery (Figure 5.1a,b) (Wang, Li et al. 2015, Xie, Wang et al. 2018). CXCR4
is expressed on a variety of AML subtypes, and AMD3100 is currently being tested for
its ability to mobilize leukemia stem cells (LSCs) from the bone marrow, as a way of
making them more susceptible to traditional chemotherapy (Nervi, Ramirez et al. 2009,
Uy, Rettig et al. 2012, Cooper, Sison et al. 2017, Martinez-Cuadron, Boluda et al. 2018).
Therefore, PCX/siRNA nanoparticles have the potential to target AML cells by two
mechanisms: inhibition of CXCR4 and delivery of knockdown constructs against critical
oncogenes.
In our study, we show that PCX is suitable for use in combination with traditional
chemotherapy, and that PCX has a potent cytotoxic effect on AML cells in vitro, which is
not observed with other CXCR4 inhibitors. Furthermore, using siRNA targeting RUNX1,
a transcription factor required in a variety of different AML subtypes, we show that
PCX/siRUNX1 polyplexes efficiently knock down RUNX1 expression in both mouse and
human leukemia cells. Importantly, PCX/siRUNX1 had a greater effect on cell viability
compared to the control. Collectively, our data demonstrate that CXCR4-targeted siRNA
nanoparticles have potential as a novel treatment for AML.
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a

b

Figure 5.1. Chemical Structure of (a) AMD3100 (Plerixafor) and (b) PCX.
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16 Results
16.1

PCX decreases leukemia cell viability in vitro
To examine the potential of PCX in AML, we used a knock-in mouse model of

inversion (16) [inv(16)] AML expressing a conditional allele of full-length Cbfb-MYH11
from the endogenous Cbfb locus (Cbfb+/56M) paired with the inducible Mx1-Cre transgene
(Kuo, Landrette et al. 2006, Hyde, Zhao et al. 2015). This knock-in mouse model
expresses the initiating oncogene, Cbfb-MYH11, at physiologically relevant levels and
develops a disease that closely resembles human inv(16) AML, making it a useful model
to test PCX. To verify that CXCR4 is expressed on Cbfb-MYH11+ leukemia cells, we
stained cells derived from three independent primary Cbfb-MYH11+/56M, Mx1-Cre+ mice
for CXCR4. We also included CSF2RB, a marker we previously showed distinguishes
leukemia stem cells (LSCs) from non-LSCs in this model (Hyde, Kamikubo et al. 2010,
Wang, Richter et al. 2019). We found that the majority of LSCs and non-LSCs from both
bone marrow and spleen express CXCR4 (Figure 5.2a). This indicates that CXCR4 is
highly expressed in leukemia cells from this mouse model.
In clinical trials, CXCR4 inhibitors have been shown to improve outcomes when
given in combination with conventional chemotherapy (Uy, Rettig et al. 2012, Cooper,
Sison et al. 2017, Martinez-Cuadron, Boluda et al. 2018). To ensure that PCX does not
diminish the effect of chemotherapy drugs, we treated Cbfb-MYH11+ leukemia cells from
three independent Cbfb-MYH11+/56M, Mx1-Cre+ mice with cytarabine (AraC) or
doxorubicin (DOXO) alone, or in combination with PCX. We used PCX at a dose of 2.1
µg/mL, which we previously showed effectively inhibits CXCR4 (Xie, Wang et al. 2018).
After 48 hours, viability was measured by flow cytometry using 4’,6-diamidino-2phenylindole (DAPI). We found that all treatment groups showed decreased viability as
compared to untreated cells (Figure 5.2b). The combination of PCX with either AraC or
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DOXO showed a trend towards decreased viability as compared to either chemotherapy
drug alone, although this difference was not statistically significant. Importantly, PCX did
not rescue the decrease in viability caused by either AraC or DOXO alone, indicating
that PCX does not block the activity of frontline chemotherapeutic agents. To confirm
that PCX has similar effects in human leukemia cells, we used the t(8;21) AML patientderived cell line, Kasumi-1, and found that PCX did not block the decreased viability
caused by either AraC or DOXO (Figure 5.2c). In addition, the combination of DOXO
and PCX caused a statistically significant decrease in viability as compared to DOXO
alone. Overall, our data imply that PCX has no adverse effect on the efficiency of
chemotherapy and could be used in combination with conventional drugs in AML
patients.
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Figure 5.2. CXCR4 is expressed on Cbfb-MYH11+ leukemia cells and decreased
leukemia cell survival in vitro.
(a) Bar graph showing the percentage of Cbfb-MYH11+ LSCs and non-LSCs that
express the CXCR4 receptor in bone marrow and spleen.
(b-c) Bar graphs showing the relative viability of mouse Cbfb-MYH11+ leukemia cells and
Kasumi-1 cells incubated with PCX (2.1μg/mL) or combined with cytotoxic drugs,
including 8 µM cytarabine (AraC) or 2 µM doxorubicin (DOXO) for 48 hours in culture.
N≥3. **P<0.01; ***P<0.001; ****P<0.0001.
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16.2

PCX has novel anti-leukemia activities
Our finding that treatment with PCX alone caused decreased leukemia cell

viability in vitro is surprising as the monomeric form of PCX, AMD3100, is not thought to
have anti-leukemia activity on its own (Nervi, Ramirez et al. 2009). This implies that the
polymeric form has novel activities. To test this possibility, leukemia cells from three
independent Cbfb-MYH11+/56M, Mx1-Cre+ mice were cultured with increasing
concentrations of PCX or AMD3100. We also tested two different synthetic peptide
CXCR4 inhibitors, BKT140 and LY2510924 (Juarez, Bradstock et al. 2003, Beider,
Begin et al. 2011, Zhang, Patel et al. 2012, Galsky, Vogelzang et al. 2014, Cho, Zeng et
al. 2015, Peng, Zhang et al. 2015). After 48 hours of treatment, viability was measured
by flow cytometry using DAPI. We found that the viability was significantly decreased by
PCX in a concentration-dependent fashion. Interestingly, none of the other CXCR4
inhibitors significantly affected cell viability, even at doses 10-20 times greater than that
of PCX (Figure 5.3a). To test whether PCX caused decreased viability via apoptosis, we
stained cells with Annexin V. We found that treatment with PCX, but not the other
CXCR4 inhibitors, increased Annexin V staining in a concentration-dependent fashion
(Figure 5.3b). To test the effect of PCX on normal cells, we treated bone marrow and
spleen cells from wild type mice with PCX in culture. For comparison, leukemia cells
from three independent Cbfb-MYH11+/56M, Mx1-Cre+ mice were incubated with PCX in
parallel. After 24 hours of treatment, we stained cells with DAPI and Annexin V. At this
time point, we found that PCX caused a trend towards decreased viability and a
statistically significant increase in Annexin V staining in mouse leukemia cells compared
to untreated cells, consistent with our previous observations. Importantly, PCX did not
affect viability or Annexin V staining in normal bone marrow or spleen cells as compared
to control (Figure 5.3c,d). These results indicate that PCX does not cause cell death in
normal hematopoietic cells. To determine if PCX cytotoxicity is associated with
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increased differentiation, we stained cells for Mac-1 and Gr-1, markers of mature
myeloid cells. We found that PCX induced a dose-dependent, statistically significant
increase of Mac-1 expression, and a trend towards increased Gr-1 expression, as
compared to the untreated cells (Figure 5.3e-g). We observed no difference in either
Mac-1 or Gr-1 expression with the other CXCR4 inhibitors. Cytospins of cells confirmed
slight features of differentiation with cells treated with PCX showing abundant cytoplasm
and cytoplasmic granules (Figure 5.3h).
To begin to address which downstream pathways could be mediating PCX’s
effect, we treated Cbfb-MYH11+ leukemia cells from three independent CbfbMYH11+/56M, Mx1-Cre+ mice with either PCX or CXCL12 alone, or the combination of
PCX and CXCL12, and analyzed two pathways that are known to be downstream of the
CXCL12/CXCR4 pathway, ERK and AKT phosphorylation (pERK and pAKT,
respectively) by western blot (Tilton, Ho et al. 2000). We found that CXCL12 did not
increase the phosphorylation of either pERK or pAKT. Neither did we observe that the
addition of PCX to CXCL12 inhibited phosphorylation of ERK and AKT. Surprisingly,
PCX alone led to an increase in pERK level as compared to the untreated (Figure
5.4a,b). To test if PCX is working through CXCR4, we treated Cbfb-MYH11+ leukemia
cells from three independent Cbfb-MYH11+/56M, Mx1-Cre+ mice with PCX alone or in
combination with increasing concentrations of CXCL12 in culture. After 48 hours of
treatment, we found that the addition of CXCL12 did not increase the viability but led to a
slight decrease in apoptosis as compared to treatment with PCX alone (Figure 5.5a,b).
In addition, we found that the addition of CXCL12 led to a trend of decrease in Mac-1 or
Gr-1 expression, even though the difference is not statistically significant (Figure
5.5c,d). Our data imply that ERK or AKT phosphorylation is not likely the downstream of
CXCL12/CXCR4 pathway in Cbfb-MYH11 expressing leukemia cells, which merits
further investigation. These results provide a possible explanation of a previous study
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showing that AMD3100 exerts its effect by binding to CXCR7 in addition to CXCR4, and
activates a GPCR-independent signaling pathway (Kim, Hwang et al. 2011).
Overall, our results indicate that PCX exhibits a more potent anti-leukemia
activity in vitro as compared to other CXCR4 inhibitors, which further supports the use of
PCX as an anti-leukemic therapy.
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Figure 5.3. PCX has novel anti-leukemia activity.
(a) Bar graph showing the relative viability of Cbfb-MYH11+ leukemia cells treated with
the indicated drugs for 48 hours in culture with different concentrations as indicated.
CXCR4 receptor in bone marrow and spleen.
(b) Bar graph showing the relative Annexin V staining of Cbfb-MYH11+ leukemia cells
treated with the indicated drugs for 48 hours in culture.
(c) Bar graphs showing the relative viability of mouse Cbfb-MYH11+ cells, normal bone
marrow and normal spleen incubated with PCX for 24 hours in culture.
(d) Bar graph showing the percentage of Annexin V+ mouse Cbfb-MYH11+ cells, normal
bone marrow and normal spleen incubated with PCX for 24 hours in culture.
(e-f) Bar graph showing the percentage of Mac-1+ (left) and Gr-1+ (right) Cbfb-MYH11+
leukemia cells treated with the indicated drugs for 48 hours in culture.
(g) Representative FACS plots gated on Mac-1 and Gr-1 in Cbfb-MYH11+ leukemia cells
treated with the indicated concentrations of CXCR4 inhibitors for 48 hours in culture.
(h) Cells treated with vehicle or PCX were adhered to slides using a cytospin, stained
with Wright-Giemsa and imaged at 100x magnification. N≥3. *P<0.05; **P<0.01;
***P<0.001. ns, not significant. Scale: 20 m.

C

C

C

X

X

X
L

C

C

L

1

X

T

2

2

12

12

C

U

L

P

C

1

0 .0

+

+

L

p -A K T /A K T

1 .0

X

X

C

X

1 .5

C

C

X

C

T

2 .5

P

P

C

P

U

p -E R K /E R K

135

a

b

1 .5

2 .0

1 .0

0 .5

0 .5

0 .0

136

Figure 5.4. PCX does not inhibit phosphorylation of AKT or ERK.
(a) Mouse Cbfb-MYH11-expressing leukemia cells were pre-treated with 1 µM PCX or
vehicle for 1 hour and were exposed to 100 ng/mL CXCL12 for 10 minutes. Western blot
of pERK, ERK, pAKT, AKT and the loading control GAPDH in Cbfb-MYH11+ leukemia
cells treated with PCX, CXCL12 or their combination.
(b) Quantification of protein levels as shown in a.

137

a

b

+

c e lls

3

R e la t iv e A n n e x in V

1 .0

0 .5

0 .0

2

1

0
2
1
L

L
X

+

2

0

0

n

n

g

g

/m

/m

L

L

C

C

X

X

C

C

C
X
C
L

d
40

4

30

3

+

(% )

(% )
20

G r-1

+

1

1
L

C
P
/m
n

c

M a c -1

2

2

X

T

g

g

0

2

n

0

+

X

0

C

P

C

0

P

1

g

C

L

1

+

n

L

C

+

X

0

/m

X

2

X

P

C

0

C

L

1

0

+

g

L

C

2

5

X

n

/m

X

1

C

C

0

C

L

L

C

2

P

P

5

/m

X

1

+

P

X

X

C

C

T

P

U

U

R e la tiv e V ia b ility

1 .5

2

1

10

0

0
U

T
P

P

C

X

+

5

0

n

C

g

P

X

/m

C

L

X

+

C

1

X

0

C

0

L

n

1

g

P

2

/m

C

L

X

+

C

2

X

0

C

0

L

n

1

g

2

/m

L

C

X

C

L

1

2

U

T
P

P

C

X

+

5

0

n

C

g

P

X

/m

C

L

X

+

C

1

X

0

C

0

L

n

1

g

P

2

/m

C

L

X

+

C

2

X

0

C

0

L

n

1

g

2

/m

L

C

X

C

L

1

2

138

Figure 5.5. CXCL12 does not reverse the apoptosis and differentiation induced by
PCX.
(a) Bar graph showing the relative viability of Cbfb-MYH11+ leukemia cells treated with
PCX alone or in combination with increasing concentrations of CXCL12 for 48 hours in
culture.
(b) Bar graph showing the relative Annexin V staining of Cbfb-MYH11+ leukemia cells
treated with PCX alone or in combination with increasing concentrations of CXCL12 for
48 hours in culture.
(c,d) Bar graph showing the percentage of Mac-1+ and Gr-1+ Cbfb-MYH11+ leukemia
cells treated with PCX or in combination with increasing concentrations of CXCL12 for
48 hours in culture.
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16.3

Runx1 knockdown increased apoptosis and decreased colony-

forming ability
In addition to inhibiting CXCR4, PCX also has the ability to encapsulate and
deliver siRNAs against critical genes. In previous work, we showed that the transcription
factor RUNX1 is required for the development of Cbfb-MYH11+ leukemia, implying that
RUNX1 is an appropriate knockdown target in frank leukemia cells (Hyde, Zhao et al.
2015). To test this possibility, we transduced leukemia cells from three independent
Cbfb-MYH11+/56M, Mx1-Cre+ mice with lentiviral vectors expressing either an shRNA
targeting Runx1 (shRunx1) or a scrambled shRNA (shSCR), and DsRed. 48 hours after
transduction, we sorted cells for DsRed expression. To test the knockdown efficiency of
shRunx1, the mRNA and protein expression levels of Runx1 were examined by qRTPCR and western blot analysis in sorted leukemia cells. We found that Runx1 mRNA
and protein were significantly lower in cells transduced with shRunx1 as compared to
shSCR transduced cells (Figure 5.6a,b). To test the effect of Runx1 knockdown on
apoptosis, we used Annexin V staining. shRunx1-transduced cells showed significantly
higher Annexin V staining as compared to cells transduced with shSCR (Figure 5.6c).
To determine the effect of Runx1 knockdown on LSC activity, we performed colony
formation assays. Equal numbers of Cbfb-MYH11+ leukemia cells transduced with
shSCR or shRunx1 were plated in methylcellulose. After 14 days of culture, colonies
were counted. We found that leukemia cells transduced with shRunx1 produced
significantly fewer colonies compared to the control group (Figure 5.6d). These results
indicate that the knockdown of Runx1 increases apoptosis and leads to decreased
colony-forming ability of Cbfb-MYH11+ leukemia cells in vitro, and that Runx1 is an
appropriate target to test the ability of PCX to deliver knockdown constructs.
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Figure 5.6. Runx1 is required in transformed Cbfb-MYH11+ leukemia cells.
(a) Bar graph showing the fold change in mRNA expression of Runx1 in Cbfb-MYH11+
leukemia cells infected with an shRNA targeting Runx1 (shRunx1) or a scrambled
control shRNA (shSCR).
(b) Western blot of Runx1 and the loading control GAPDH in Cbfb-MYH11+ leukemia
cells infected with shRunx1 and shSCR; dotted line indicates the division between two
different parts of the same blot.
(c) Bar graph showing the percentage of Annexin V+ leukemia cells 48 hours after
transduction with lentiviral vectors expressing the indicated shRNA constructs.
(d) Bar graph showing the relative number of colonies formed from leukemia cells
infected with shRunx1 or shSCR after 14 days in culture. N=3. *P < 0.05; ***P< 0.001.
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16.4

PCX condenses siRNA to form nanoparticles
The capability of PCX to form nanoparticles with siRNA was first validated using

a gel retardation assay. Nanoparticles were prepared by mixing PCX with siRNA solution
at increasing PCX/siRNA ratios. PCX fully encapsulated siRNA at and above
PCX/siRNA (w/w) ratios of 2 (Figure 5.7a). Hydrodynamic size and ζ-potential of the
prepared PCX/siRNA nanoparticles (w/w = 2) were measured by dynamic light
scattering. Nanoparticles presented size of 63.3 ± 0.9 nm with low dispersity index (0.14)
(Figure 5.7b) and positive surface charge with ζ potential of 18.2 ± 0.7 mV (Figure
5.7c). The morphology of the nanoparticles was analyzed by transmission electron
microscopy (TEM). We observed uniform particles with mostly spherical morphology
(Figure 5.7d). The release of siRNA from the nanoparticles was studied by heparin
displacement assay. Nanoparticles completely released siRNA after incubation with
heparin concentrations above 120 μg/mL (Figure 5.7e).
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Figure 5.7. Physicochemical characterization of PCX/siRNA nanoparticles.
(a) siRNA condensation by PCX using agarose gel electrophoresis.
(b) Hydrodynamic size distribution of PCX/siRNA nanoparticles (w/w=2).
(c) ζ-potential of PCX/siRNA nanoparticles (w/w=2).
(d) Transmission electron microscopy (TEM) image of PCX/siRNA nanoparticles
(w/w=2).
(e) Heparin-induced siRNA release from the PCX/siRNA nanoparticles (w/w=2) with
increasing concentration of heparin.
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16.5

Runx1 knockdown by PCX/siRunx1 polyplexes
Before testing the ability to deliver siRNA by PCX, we first examined whether

PCX can be efficiently internalized by leukemia cells. We incubated Cbfb-MYH11+
leukemia cells with nanoparticles prepared with Alexa Fluor 647-labeled PCX polymers
(AF647-PCX) for 72 hours. Cells were then treated with a light detergent wash to strip
them of cell surface proteins. An antibody against the cell surface receptor KIT, which is
highly expressed in Cbfb-MYH11+ leukemia cells, was used as a control for stripping
(Hyde, Kamikubo et al. 2010). We found that nearly all PCX-AF647-treated cells (99%)
were fluorescent after stripping and showed no significant difference in the percentage of
fluorescent cells compared to unstripped cells. This indicates that the majority of the
nanoparticles were efficiently internalized by leukemia cells and that little PCX remained
on the extracellular surface. In contrast, in cells stained with the KIT antibody, which is
not expected to be internalized, the detergent wash led to the loss of fluorescent signal,
indicating that cell surface proteins were effectively stripped from the plasma membrane
(Figure 5.8a). To evaluate the ability of PCX/siRNA nanoparticles to deliver siRNA to
Cbfb-MYH11+ leukemia cells, we formulated PCX with siRNA targeting Runx1
(PCX/siRunx1) or a negative control siRNA (PCX/siNC). We treated leukemia cells from
three independent Cbfb-MYH11+/56M, Mx1-Cre+ mice with PCX/siRunx1 or PCX/siNC for
6 hours and analyzed Runx1 expression by qRT-PCR. We found that cells treated with
PCX/siRunx1 showed a significant decrease in Runx1 expression (Figure 5.8b). To test
if the knockdown of Runx1 using PCX/siRunx1 caused defects on cell survival, we
stained the cells treated with PCX/siRunx1 and PCX/siNC with Annexin V. We found that
PCX/siRunx1 treatment led to an increase in the percentage of Annexin V+ cells
(average 40.5%, +/-1.6) as compared to the cells treated with PCX/siNC particles
(average 36.5%, +/-1.4). In addition, the percentage of Annexin V+ cells from PCX/siNC
treatment was significantly higher than that of untreated cells, consistent with our
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analysis that PCX has anti-leukemia activity on its own (Figure 5.8c). Collectively, our
results indicate that PCX can efficiently deliver siRNA to Cbfb-MYH11+ leukemia cells in
vitro and cause apoptosis.
To test if PCX delivers siRUNX1 to human AML cells, we used Kasumi-1 cells,
as they have also been shown to require RUNX1 expression for survival (Ben-Ami,
Friedman et al. 2013). We treated Kasumi-1 cells with PCX/siRUNX1 or PCX/siNC
nanoparticles. The expression of RUNX1 was significantly decreased within 6 hours in
cells cultured with PCX/siRUNX1 as compared to those with PCX/siNC (Figure 5.8d). In
addition, the percentage of Annexin V+ cells from PCX/siRUNX1 treatment was
significantly higher than cells cultured with PCX/siNC (Figure 5.8e). These findings
indicate that PCX efficiently delivered siRUNX1 to human leukemia cells and causes
increased apoptosis as compared to PCX/siNC. Thus, our study indicates that PCX is
able to deliver siRNA targeting important regulators of leukemia cells and has
therapeutic potential to treat patients with AML.
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Figure 5.8. Intracellular uptake and gene silencing effects in Cbfb-MYH11+
leukemia cells treated with siRUNX1 delivered by CXCR4-targeted nanoparticles in
vitro.
(a) FACS plots of the number of cells with Alexa Fluor 647 (AF647) before and after
stripping of cells surface proteins and treated with either a labeled antibody against KIT
or with AF647-labeled PCX.
(b) Bar graph showing the fold change in mRNA expression of Runx1 in Cbfb-MYH11+
leukemia cells treated with PCX coupled with either Runx1 siRNA (PCX/siRunx1) or
non-targeting siRNA (PCX/siNC) for 6 hours in culture.
(c) Bar graph showing the percentage of Annexin V+ leukemia cells either untreated,
treated with PCX/siNC, or treated with PCX/siRunx1 for 24 hours in culture.
(d) Bar graph showing the fold change in mRNA expression of RUNX1 in Kasumi-1 cell
line treated with PCX coupled with either RUNX1 siRNA (PCX/siRUNX1) or nontargeting siRNA (PCX/siNC) for 6 hours in culture.
(e) Bar graph showing the percentage of Annexin V+ Kasumi-1 cells either untreated,
treated with PCX/siNC, or treated with PCX/siRUNX1 for 6 hours in culture. N ≥ 3. *P
<0.05; **P <0.01; ***P <0.001.
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17 Discussion
Despite the recent development of several targeted inhibitors for the treatment of
AML, there remain significant populations of patients with relapsed or refractory disease
for whom there are few effective treatment options (Gu, Yang et al. 2018, Luppi,
Fabbiano et al. 2018). This is in part related to the heterogeneity of AML. Unlike many
solid tumors, there is not a single driver mutation present in the majority of AML patient
samples (Cancer Genome Atlas Research, Ley et al. 2013). siRNA-based therapy has
emerged as a novel therapeutic approach for treating AML, as it is highly specific and
customizable, providing the flexibility of targeting different oncogenes (Cioca, Aoki et al.
2003, Landry, Aliabadi et al. 2012, Gul-Uludag, Valencia-Serna et al. 2014, Uludag,
Landry et al. 2016).
In this study, we characterized a polymeric CXCR4 antagonist (PCX) which is
capable of delivering siRNAs in leukemia cells. We showed that PCX has a cytotoxic
effect in AML cells in vitro. We also found that treatment with PCX increased expression
of the mature myeloid marker Mac-1, suggesting that PCX induces the terminal
differentiation of leukemia cells. Multiple agents have been developed and tested for
CXCR4-targeted therapy including the small molecule inhibitor AMD3100 and the
peptide CXCR4 inhibitors BKT140 and LY2510924 (Azab, Runnels et al. 2009, Cho,
Zeng et al. 2015, Abraham, Klein et al. 2017). Interestingly, when we directly compared
PCX with AMD3100, BKT140 and LY2510924, we found that none of the other inhibitors
showed anti-leukemic activity in vitro, even at 10-20 times higher concentrations. This
was expected with AMD3100, as previous work has indicated that AMD3100 alone does
not affect leukemia cell survival, and that its clinical utility stems from its ability to
mobilize leukemia cells out of the protective microenvironment (Nervi, Ramirez et al.
2009). However, previous studies using LY2510924 and BKT140 have shown effects on
viability and differentiation in AML cells (Cho, Zeng et al. 2015, Abraham, Klein et al.

150

2017). Although we did not observe such effects in our study, these previous findings
imply that the anti-leukemic effects of PCX are likely due to enhanced inhibition of
CXCR4, potentially due to a multivalency effect. This is further supported by studies
using the humanized anti-CXCR4 antibodies Ulocuplumab and PF-0674714, which both
exhibit anti-leukemic activity both in vitro and in vivo (Kuhne, Mulvey et al. 2013, Liu, Gu
et al. 2017). In fact, our preliminary data showed that CXCL12 treatment alone did not
increase either ERK or AKT phosphorylation, and the addition of CXCL12 only led to a
slight decrease in differentiation status as compared to PCX alone. These results
indicate that ERK and AKT phosphorylation are not likely regulated by CXCL12/CXCR4
signaling in Cbfb-MYH11+ leukemia cells, and PCX might have nonspecific binding
activity. Our study also further explains a previous study showing that AMD3100 exerts
its effect on leukemia cells by interacting with CXCR7 in addition to CXCR4 (Kim, Hwang
et al. 2011).
Another advantage of PCX is its ability to act as an siRNA delivery vehicle
(Wang, Li et al. 2015, Xie, Wang et al. 2018). In this “proof of concept” study, we used
RUNX1 as a knockdown target as its expression is required in leukemia cells of multiple
different subtypes (Ben-Ami, Friedman et al. 2013, Goyama, Schibler et al. 2013, Hyde,
Liu et al. 2017). We found that PCX successfully delivered siRNAs against RUNX1 and
caused decreased RUNX1 expression in both mouse Cbfb-MYH11+ cells and human
AML cells. This implies that PCX has potential as a nucleic acid delivery vehicle to AML
cells. For use in patients, RUNX1 may not be the most appropriate target. Although
genetic loss or complete knockdown of RUNX1 causes cell death in many AML
subtypes, a more recent study showed that a moderate level of RUNX1 expression
paradoxically promotes leukemogenesis (Ben-Ami, Friedman et al. 2013, Hyde, Zhao et
al. 2015, Morita, Maeda et al. 2017). However, as siRNAs are highly customizable, this
approach could be used to target other leukemogenic oncogenes. Leukemic fusion
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genes are a particularly attractive target as they are likely expressed in all leukemia cells
in a sample, but not in healthy cells (Wang, Wu et al. 2017).
Based on these data, we propose the following model of action of PCX/siRNA
nanoparticles (Figure 5.9). PCX inhibits CXCR4, leading to mobilization from bone
marrow and increased sensitivity to chemotherapy, similar to AMD3100. However, PCX
also causes cell death and terminal differentiation, which further decreases leukemic
burden. More importantly, PCX is also able to deliver siRNAs capable of silencing critical
oncogenes. Due to its multi-functionality, PCX has potential for the treatment of patients
who cannot tolerate traditional chemotherapy, or whose disease is refractory to such
treatments. Collectively, our work indicates that PCX has potential as an effective
treatment for patients with AML.
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Figure 5.9. Proposed mechanism of action of PCX/siRNA nanoparticles for
treatment of acute myeloid leukemia.
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CHAPTER VI
Summary and Future Directions
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18 Summary
Inv(16) AML generates a fusion gene called CBFB-MYH11, which occurs in 1015% of AML cases (Xiaosu, Leqing et al. 2019). Approximately 50% of patients with inv(16)
AML eventually relapse, which is thought to be caused by the existence of leukemia stem
cells (LSCs) that are resistant to current treatments. Therefore, targeting the LSC
population represents a promising strategy for anti-leukemia therapy. In addition to LSCtargeted therapy, fusion proteins also represent potential therapeutic targets in treating
AML. One main reason is that the fusion gene products are specifically expressed in
leukemia cells but not in normal tissues. By developing small molecules or drugs that
specifically inhibit fusion protein activity, it is very likely that the whole leukemic population
including the LSC population would be eradicated, preventing relapse.
Previous studies by Hyde et al identified the cytokine receptor CSF2RB is
upregulated in Cbfb-MYH11-expressing cells, and LSCs are enriched in CSF2RB- cells
(Hyde, Kamikubo et al. 2010). By futher sorting leukemia cells into different LSC subpopulations based on the expression fo IL1RL1 and KIT, we found that LSCs exist in
multiple fractions, as defined by their immunophenotype. Thus, our data indicate that the
LSC population is much more heterogeneous than previously thought. In addition, our
results imply that IL1RL1/IL-33 axis is a potential therapeutic target for future AML
treatment. Importantly, our observations are consistent with a previous study
demonstrating that expression of the human HSPCs markers CD34 and CD38 is highly
plastic, and those two markers are not strictly arranged in a hierarchical pattern (Quek,
Otto et al. 2016, Lang, Wojcik et al. 2017). Thus, our data imply that it remains challenging
to identify specific markers of LSCs in order to target them. An alternative approach of
targeting LSCs is to inhibit the oncoproteins that drive their behavior.
To better understand the role of Cbfb-MYH11 after leukemic transformation, we
developed a new knock-in mouse model where the MYH11 tail is flanked by loxP sites,
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allowing for deletion of Cbfb-MYH11 in transformed leukemia cells. We found that loss of
Cbfb-MYH11 in vitro led to increased apoptosis and decreased colony-forming ability. By
using a doxycycline (DOX) inducible-shRNA against MYH11 to knockdown expression of
Cbfb-MYH11, wefound that knockdown of the fusion gene led to decreased leukemic
burden, increased differentiation and prolonged survival as compared to the control.
Interestingly, after long-term treatment with DOX, some mice showed a return of leukemia
cells transduced with the shRNA construct. This implies that, unlike the bulk leukemic
population, LSCs with Cbfb-MYH11 knockdown may still be able to survive and reinitiate
leukemia with the accumulation of additional mutations. The molecular consequences of
those cooperating mutations may lead to either a regain of Cbfb-MYH11 expression in the
LSC population or activation of prosurvival signaling pathways. This question merits
further investigation. Our study also implies that solely targeting Cbfb-MYH11 may not be
sufficient to eradicate LSCs in AML, and uncovering additional strategies to target the LSC
population may be necessary for preventing relapse. In fact, our results are consistent with
the previous finding that LSCs do not strictly depend on Bcr-Abl to survive in CML
(Hamilton, Helgason et al. 2012, Hamad, Sahli et al. 2013). Taken together, these results
have firmly shifted our focus toward oncogenic driver-independent resistance
mechanisms. One potential approach to overcome the problem is to mobilize the LSCs
from the BM niche by adopting CXCR4 inhibitors.
As a proof-of-concept study, we successfully tested a CXCR4-inhibiting
polycations (PCX), which is able to inhibit CXCR4 activity and deliver siRNAs into target
cells (Wang, Li et al. 2015, Wang, Kumar et al. 2016). CXCR4 is expressed on a variety
of AML subtypes and is important for the interaction between leukemia cells and the
bone marrow microenvironment (Walenkamp, Lapa et al. 2017). An FDA-approved
CXCR4 inhibitor, AMD3100, has shown the ability of increasing chemosensitivity of AML
cells by mobilizing leukemia cells into the blood circulation (Nervi, Ramirez et al. 2009).
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Our study provides evidence on the potential to use of PCX/siRNA nanoparticles to
decrease leukemia cells survival, andindicates that PCX/siRNA has a potential
therapeutic value for treatment of AML patients. Surprisingly, we found that CXCL12, the
ligand for CXCR4, did not increase phosphorylation of either pERK or pAKT of leukemia
cells, which are well-known downstream targets of CXCL12/CXCR4 axis (Tilton, Ho et
al. 2000). In addition, leukemia cells treated with CXCL12 did not show reversed
phenotypes, as compared to cells treated with PCX alone. Thus, our data imply that the
anti-leukemic effect by PCX is not likely to solely rely on CXCR4 signaling, and there
might be nonspecific binding sites for PCX to target, further causing cell death. Previous
studies demonstrate that AMD3100 binds to CXCR7, which regulates a different
signaling pathway from CXCL12/CXCR4 axis (Kim, Hwang et al. 2010, Kim, Hwang et
al. 2011). Thus, CXCR7 is a potential mediator of PCX’s anti-leukemic effect.

19 Future Directions
19.1 The mechanism of blocking IL1RL1/IL-33 axis in AML
Our data indicate that the IL1RL1/IL-33 axis is important for the survival of
leukemia cells in vitro, implying that targeting the IL1RL1/IL-33 axis may have potential
as a new therapeutic target in AML. This would first need to be verified in vivo using the
Cbfb-MYH11 knock-in mouse model using and anti-IL1RL1 blocking antibody or shRNA
specifically targeting IL1RL1. However, IL-33 is an important cytokine in regulating
immune cell activity, including T cells, mast cells, and basophils (Liew, Pitman et al.
2010). Therefore, it will be important to test if blocking IL33/IL1RL1 in leukemia cells is
disrupting immune cell activity. Overall, these data will shed light on the mechanism of
IL1RL1 signaling in inv(16) AML. Furthermore, understanding the relationship between
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blocking IL1RL1/IL-33 axis and immune response will determine the potential of blocking
IL1RL1 signaling for the treatment of AML.
We also observed the dynamic property of IL1RL1 and KIT as LSC markers,
indicating that it will be important to examine if the markers for LSCs in other subtypes of
AML also show plasticity. These proposed studies would help shed light on
characterizing LSC activity and exploring more specific biomarkers to target LSCs in
AML.

19.2 The mechanism of Cbfb-MYH11 loss in leukemia cells
Our current data indicate that loss of Cbfb-MYH11 increases cell death, causes
apoptosis and decreases leukemic burden both in vitro and in vivo. Thus, it will be
important to understand potential downstream targets of Cbfb-MYH11, especially those
that have important functional roles in AML such as differentiation, apoptosis or drug
resistance. Previous study using the human inv(16) cell line, ME-1 provides evidence
that CBFB-MYH11 knockdown causes both activation and repression of gene
expression (Mandoli, Singh et al. 2014). Among those target genes of CBFB-MYH11,
they found genes associated with stem cell activity, including ID1, LMO1 and JAG1, as
well as differentiation (Mandoli, Singh et al. 2014). Future study should focus on verifying
if Cbfb-MYH11 regulates the expression of those genes in genetic mouse models of
inv(16) AML and patient samples. Eventually, these studies may also help us to achieve
the goal of developing novel therapeutic strategies in both inv(16) AML and other
subtypes of AML.
In addition, our preliminary data also imply that a rare population of leukemia
cells, such as LSCs, may survive with the loss of Cbfb-MYH11. Our preliminary data are
consistent with our current understanding of CML which is caused by the oncogene Bcr-
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Abl, where LSCs do not depend on Bcr-Abl to survive (Hamilton, Helgason et al. 2012,
Hamad, Sahli et al. 2013). Understanding Cbfb-MYH11-independent mechanisms of
LSCs would shed light on important signaling pathways or additional mutations that are
required for LSCs to survive or become resistant to current treatments. This finding will
further help us to develop more effective LSC-targeted therapy in different types of AML.

19.3 Clinical application of PCX and the ability of PCX/siRNA nanoparticles
to other target genes
Our study supports the development of PCX/siRNA as a novel treatment for AML
patients. Future studies will focus on testing the effect of simultaneous inhibiting CXCR4
and delivering siRNA against Cbfb-MYH11 both in vitro and in vivo. However, our
preliminary data imply that LSCs may not completely rely on the expression of CbfbMYH11 to survive. If that is the case, it will be interesting to design siRNA constructs
specific to cooperating mutations that are acquired by LSCs when Cbfb-MYH11
expression is lost.
More importantly, we found that PCX induces myeloid differentiation. That
property is different from the FDA-approved CXCR4 antagonist AMD3100, which mainly
mobilizes leukemia cells into the circulation (Nervi, Ramirez et al. 2009, Uy, Rettig et al.
2012, Cooper, Sison et al. 2017). Therefore, understanding the mechanism mediated by
PCX will be important for the application of PCX in treating AML. However, since
AMD3100 is clinically used to mobilize HSCs during transplantation, the potential that
PCX causes differentiation of HSCs needs to be taken into consideration. Thus, further
understanding of PCX activity in leukemia cells will be necessary prior to clinical
implementation of PCX. Overall, our study will justify the use of PCX in combination with
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traditional chemotherapeutic agents for treatment of AML patients, as well as make use
of PCX to silence more oncogenes important for LSC maintenance in various types of
AML.
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